{"ticker": {"uuid": "623924bc-d175-483e-98a6-d82304cdb374", "symbol": "BLTE", "name": "Belite Bio Inc ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "charts": {"tiers": [{"count": 39, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 17, "label": "Earnings"}, {"count": 10, "label": "Analyst action"}, {"count": 9, "label": "Market update"}, {"count": 2, "label": "Regulatory and legal"}, {"count": 1, "label": "Balance sheet"}], "sources": [{"label": "Investing.com", "count": 6}, {"label": "MarketBeat", "count": 6}, {"label": "Stock Titan", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "www.marketscreener.com", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Sahm", "count": 2}, {"label": "marketscreener.com", "count": 1}]}, "insights": [{"text": "Early balanced news score", "tone": "neutral", "label": "Weighted tone", "value": "56/100"}, {"text": "6.62 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "32/100"}, {"text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "tone": "neutral", "label": "Market reaction", "value": "Early company-news score"}, {"text": "75/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Earnings"}, {"text": "96% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "39"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "positive", "label": "Evidence agreement", "value": "11/100"}, {"text": "+27.6% over one week, +18.7% over four weeks, trend inactive, and materially above fair value.", "tone": "negative", "label": "Trend context", "value": "Trend inactive"}, {"text": "Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating", "tone": "positive", "label": "Latest direct headline", "value": "Positive"}], "classifier": {"events": [{"count": 17, "event": "earnings", "label": "Earnings", "weight": 10.82}, {"count": 10, "event": "analyst", "label": "Analyst action", "weight": 7.1}, {"count": 9, "event": "general", "label": "Market update", "weight": 5.58}, {"count": 2, "event": "regulatory", "label": "Regulatory and legal", "weight": 1.15}, {"count": 1, "event": "liquidity", "label": "Balance sheet", "weight": 0.6}], "pipeline": {"status": "healthy", "providers_attempted": 4, "providers_with_results": 4, "raw_articles": 131, "unique_stories": 56, "duplicates_removed": 75, "relevant_stories": 39, "matched_archive_stories": 42, "current_evidence": 23, "direct_evidence": 39, "archive_articles": 6, "durable_story_count": 43, "durable_evidence_used": true, "durable_collected_at": "2026-09-05T05:20:27.428529+00:00"}, "confidence": 75, "primary_event": "earnings", "primary_label": "Earnings", "negative_events": 7, "positive_events": 16}, "updated_at": "2026-09-07T13:33:58.879792+00:00", "total_unique": 43, "total_fetched": 43, "interpretation": {"tone": "neutral", "label": "Early company-news score", "risks": [], "badges": ["Provisional evidence"], "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 32, "event_label": "Earnings", "opportunities": [], "classification": "provisional", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "negative", "latest_week": "2026-09-04", "trend_label": "Trend inactive", "latest_close": 193.61, "trend_signal": "0", "one_week_move": 27.6, "reaction_tone": "positive", "fair_value_gap": 133.2, "four_week_move": 18.7, "reaction_label": "Price confirming higher", "fair_value_tone": "negative", "market_dynamics": 0.777583, "market_sentence": "+27.6% over one week, +18.7% over four weeks, trend inactive, and materially above fair value.", "fair_value_label": "Materially above fair value", "twelve_week_move": 40.1, "relative_strength": 20.499339, "has_market_context": true, "expectation_direction": "undecided", "expectation_probability": 53.6908, "market_dynamics_buy_signal": false}, "total_relevant": 39, "pipeline_health": {"status": "healthy", "providers_attempted": 4, "providers_with_results": 4, "raw_articles": 131, "unique_stories": 56, "duplicates_removed": 75, "relevant_stories": 39, "matched_archive_stories": 42, "current_evidence": 23, "direct_evidence": 39, "archive_articles": 6, "durable_story_count": 39, "durable_evidence_used": true, "durable_collected_at": "2026-09-07T13:33:58.879792+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Early balanced news score", "score": 56, "total": 43, "neutral": 16, "negative": 7, "positive": 16, "raw_score": 66, "confidence": 32, "dispersion": 11, "story_count": 39, "window_days": 30, "direct_share": 96, "source_count": 14, "score_version": "evidence-v10", "evidence_count": 23, "evidence_status": "provisional", "information_mass": 0.606, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-09-04T19:40:09+00:00", "direct_story_count": 39, "effective_articles": 6.62, "sector_story_count": 0, "direct_source_count": 14, "industry_story_count": 0, "source_concentration": 0.3068, "directional_story_count": 23}, "articles": [{"url": "https://www.marketscreener.com/news/belite-bio-shares-rise-after-canaccord-initiates-coverage-with-buy-rating-ce785bdbd980f126", "tier": "direct", "title": "Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio's shares rose after Canaccord Genuity initiated coverage with a Buy rating and a $303 price target. This positive analyst coverage comes amidst other recent news for Belite Bio, including FDA Priority Review for its Stargardt Disease treatment, Tinlarebant. The company is focused on developing therapeutics for retinal degenerative eye diseases and metabolic conditions.", "age_days": 2.7, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/belite-bio-shares-rise-after-canaccord-initiates-coverage-with-buy-rating-ce785bdbd980f126", "source_name": "marketscreener.com", "published_at": "2026-09-04T19:40:09", "tone_signals": ["Analyst upgrade"], "company_focus": 0.78, "freshness_pct": 53.0, "sentiment_pct": 75, "evidence_basis": "archived_article", "evidence_share": 15.8, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.095502, "influence_label": "High", "event_confidence": 69, "company_focus_pct": 78, "evidence_strength": 58, "published_display": "04 Sep 2026 19:40", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "15.8"}, {"url": "https://finance.yahoo.com/healthcare/articles/belite-bio-apos-tinlarebant-revenue-153246252.html", "tier": "direct", "title": "Belite Bio's Tinlarebant Revenue Estimates Have Multiple Drivers of Upside, Mizuho Says", "topics": [], "summary": "", "age_days": 2.9, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/belite-bio-apos-tinlarebant-revenue-153246252.html", "source_name": "MT Newswires", "published_at": "2026-09-04T15:45:37+00:00", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 66.8, "sentiment_pct": 57, "evidence_basis": "headline_only", "evidence_share": 12.6, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.076222, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 45, "published_display": "04 Sep 2026 15:45", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "12.6"}, {"url": "https://m.investing.com/news/analyst-ratings/canaccord-initiates-belite-bio-stock-with-buy-on-stargardt-therapy-93CH-4889421?ampMode=1", "tier": "direct", "title": "Canaccord initiates Belite Bio stock with buy on Stargardt therapy", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Canaccord Genuity initiated coverage on Belite Bio, Inc, ADR (NASDAQ:BLTE) with a buy rating and a $303 price target, citing optimism for its Stargardt disease therapy, Tinlarebant. The drug has shown significant efficacy in trials and has an FDA PDUFA date set for February 12, 2027. Belite Bio also reported a smaller-than-expected loss for Q2 2026 and possesses strong liquidity to fund its U.S. launch.", "age_days": 3.1, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://m.investing.com/news/analyst-ratings/canaccord-initiates-belite-bio-stock-with-buy-on-stargardt-therapy-93CH-4889421?ampMode=1", "source_name": "Investing.com", "published_at": "2026-09-04T11:40:09", "tone_signals": ["Analyst upgrade", "Buy Rating"], "company_focus": 1.0, "freshness_pct": 49.1, "sentiment_pct": 74, "evidence_basis": "archived_article", "evidence_share": 25.4, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.15375, "influence_label": "High", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 60, "published_display": "04 Sep 2026 11:40", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "25.4"}, {"url": "https://finance.yahoo.com/markets/stocks/articles/canaccord-genuity-initiates-belite-bio-095227716.html", "tier": "direct", "title": "Canaccord Genuity Initiates Belite Bio at Buy With $303 Price Target", "topics": [], "summary": "", "age_days": 3.2, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/canaccord-genuity-initiates-belite-bio-095227716.html", "source_name": "MT Newswires", "published_at": "2026-09-04T09:52:27+00:00", "tone_signals": ["Analyst upgrade"], "company_focus": 1.0, "freshness_pct": 48.3, "sentiment_pct": 69, "evidence_basis": "headline_only", "evidence_share": 11.8, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.071611, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 53, "published_display": "04 Sep 2026 09:52", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "11.8"}, {"url": "https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-belite-bio-stock-rating-on-commercial-plans-93CH-4887644?ampMode=1", "tier": "direct", "title": "H.C. Wainwright reiterates Belite Bio stock rating on commercial plans", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "H.C. Wainwright has reiterated a Buy rating and a $214 price target for Belite Bio (NASDAQ:BLTE) due to its commercial plans for tinlarebant, a Stargardt disease treatment. The company aims for a March 2027 launch, pending FDA approval, and has outlined a comprehensive commercial strategy with a strong balance sheet to support it. Belite Bio also reported better-than-expected Q2 2026 earnings and received Priority Review for its New Drug Application.", "age_days": 3.7, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-belite-bio-stock-rating-on-commercial-plans-93CH-4887644?ampMode=1", "source_name": "Investing.com", "published_at": "2026-09-03T20:40:09", "tone_signals": ["Fda Approval", "Buy Rating"], "company_focus": 1.0, "freshness_pct": 42.5, "sentiment_pct": 64, "evidence_basis": "archived_article", "evidence_share": 17.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.103902, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 48, "published_display": "03 Sep 2026 20:40", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "17.1"}, {"url": "https://finance.yahoo.com/m/2cb87858-4af2-3f04-85fa-20d62548d58e/belite-bio-wins-fda-priority.html", "tier": "direct", "title": "Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease", "topics": ["Finance", "Financial Markets", "Life Sciences"], "summary": "Belite Bio has received FDA Priority Review for its new drug application for tinlarebant to treat Stargardt disease type 1, with a PDUFA date set for February 12, 2027. If approved, tinlarebant would be the first treatment for this rare inherited retinal disease, having shown a 35.7% reduction in retinal lesion growth in Phase III trials. The company is actively preparing for commercial launch, including building sales infrastructure, physician education programs, and patient support services, targeting an estimated 53,000 U.S. patients.", "age_days": 4.4, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/2cb87858-4af2-3f04-85fa-20d62548d58e/belite-bio-wins-fda-priority.html", "source_name": "MarketBeat", "published_at": "2026-09-03T04:01:58+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 21.8, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.010422, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "03 Sep 2026 04:01", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.marketscreener.com/news/belite-bio-to-participate-in-four-upcoming-investor-conferences-ce7858ddd18df321", "tier": "direct", "title": "Belite Bio to Participate in Four Upcoming Investor Conferences", "topics": ["Clinical Trials", "Finance", "Healthcare", "Life Sciences", "Retinal Diseases"], "summary": "Belite Bio, Inc (NASDAQ: BLTE) announced its participation in four upcoming investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference, 2026 Cantor Global Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The company, a clinical-stage drug developer focusing on degenerative retinal diseases, will present at these events through fireside chats. Webcasts of these presentations will be available on Belite Bio's investor relations website for 90 days.", "age_days": 6.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/belite-bio-to-participate-in-four-upcoming-investor-conferences-ce7858ddd18df321", "source_name": "www.marketscreener.com", "published_at": "2026-09-01T12:19:45", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 12.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "evidence_weight": 0.007662, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "01 Sep 2026 12:19", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/news/BLTE/belite-bio-to-host-virtual-commercial-day-on-september-2-pdcyu0o78vgf.html", "tier": "direct", "title": "The FDA set Feb. 12, 2027, for reviewing a Stargardt disease drug", "topics": ["Earnings", "Life Sciences"], "summary": "Belite Bio (NASDAQ: BLTE) will host a Virtual Commercial Day on September 2, 2026, to discuss its lead candidate, tinlarebant, for Stargardt disease type 1 (STGD1). The FDA has granted Priority Review for tinlarebant's New Drug Application, with a Prescription Drug User Fee Act (PDUFA) date set for February 12, 2027. The event will feature management, ophthalmology experts, and patients, covering disease overview, unmet needs, treatment landscape, and commercial opportunities if the drug is approved.", "age_days": 13.7, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/news/BLTE/belite-bio-to-host-virtual-commercial-day-on-september-2-pdcyu0o78vgf.html", "source_name": "Stock Titan", "published_at": "2026-08-24T20:14:47", "tone_signals": ["Contract or approval won"], "company_focus": 0.86, "freshness_pct": 14.9, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.018853, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 86, "evidence_strength": 0, "published_display": "24 Aug 2026 20:14", "direction_included": false, "company_focus_label": "Company discussed", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://markets.businessinsider.com/news/stocks/belite-bio-to-host-virtual-commercial-day-on-september-2-2026-1036487980", "tier": "direct", "title": "Belite Bio to Host Virtual Commercial Day on September 2, 2026", "topics": ["Clinical Trials", "Fda Approval", "Finance", "Life Sciences", "Ophthalmology"], "summary": "Belite Bio will host a Virtual Commercial Day on September 2, 2026, to discuss Stargardt disease type 1 (STGD1), unmet medical needs, and the commercial opportunity for their drug tinlarebant. The event will feature Belite Bio's management, ophthalmology experts, and individuals with STGD1, following the FDA's recent acceptance and Priority Review designation for tinlarebant's New Drug Application. The FDA has set a Prescription Drug User Fee Act date of February 12, 2027.", "age_days": 13.7, "is_stale": false, "sentiment": "neutral", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://markets.businessinsider.com/news/stocks/belite-bio-to-host-virtual-commercial-day-on-september-2-2026-1036487980", "source_name": "markets.businessinsider.com", "published_at": "2026-08-24T20:14:47", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 25.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 3, "evidence_weight": 0.021751, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "24 Aug 2026 20:14", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/news/BLTE/belite-bio-announces-oral-presentations-at-two-upcoming-medical-13ib6bj138hv.html", "tier": "direct", "title": "Belite Bio sets four talks at two medical meetings, including Phase 3 data", "topics": ["Life Sciences"], "summary": "Belite Bio (NASDAQ: BLTE) announced that data from its Phase 3 DRAGON study of tinlarebant for Stargardt disease will be presented at two major ophthalmology meetings in August 2026: the SOG Annual Congress in Lausanne and the APVRS Congress in Gold Coast. The presentations will include results from the Phase 3 DRAGON study in adolescent and adult Stargardt disease, new insights, and updates on ABCA4-retinopathy therapy trials in Japan. Tinlarebant is a novel oral therapy aimed at reducing bisretinoid accumulation, which causes retinal disease.", "age_days": 16.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/news/BLTE/belite-bio-announces-oral-presentations-at-two-upcoming-medical-13ib6bj138hv.html", "source_name": "Stock Titan", "published_at": "2026-08-21T15:10:46", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000176, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Aug 2026 15:10", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.globenewswire.com/de/news-release/2026/08/21/3349036/0/en/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences.html", "tier": "direct", "title": "Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences", "topics": ["Clinical Trials", "Life Sciences", "Novel Therapeutics", "Ophthalmology", "Stargardt Disease"], "summary": "Belite Bio, Inc. (NASDAQ: BLTE) will present data from its clinical trials at two upcoming medical conferences: the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress. The presentations will focus on results from the Phase 3 DRAGON study of tinlarebant for adolescent and adult Stargardt Disease. Tinlarebant is an oral therapy designed to reduce vitamin A-based toxins associated with degenerative retinal diseases.", "age_days": 16.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/de/news-release/2026/08/21/3349036/0/en/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences.html", "source_name": "GlobeNewswire", "published_at": "2026-08-21T15:10:46", "tone_signals": ["Negative financial language"], "company_focus": 0.78, "freshness_pct": 0.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "evidence_weight": 0.000172, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "21 Aug 2026 15:10", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.quiverquant.com/news/Belite+Bio+Announces+Tinlarebant+Data+Presentations+at+SOG+and+APVRS+Congresses", "tier": "direct", "title": "Belite Bio Announces Tinlarebant Data Presentations at SOG and APVRS Congresses", "topics": ["Earnings", "Life Sciences"], "summary": "Belite Bio, Inc. (NASDAQ: BLTE) will present data on its lead therapy, tinlarebant, at two upcoming ophthalmology congresses in Switzerland and Australia. The presentations will focus on the results from the Phase 3 Dragon Study, which evaluated tinlarebant for treating Stargardt disease, an inherited macular dystrophy with no approved treatments. Tinlarebant works by reducing toxic bisretinoid accumulation in the retina and has received several designations to expedite its development.", "age_days": 17.1, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.quiverquant.com/news/Belite+Bio+Announces+Tinlarebant+Data+Presentations+at+SOG+and+APVRS+Congresses", "source_name": "Quiver Quantitative", "published_at": "2026-08-21T12:12:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 9.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.009023, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Aug 2026 12:12", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.marketbeat.com/instant-alerts/belite-bio-nasdaqblte-stock-rating-lowered-by-zacks-research-2026-08-20", "tier": "direct", "title": "Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Zacks Research", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Zacks Research has downgraded Belite Bio (NASDAQ:BLTE) from a \"strong buy\" to a \"hold\" rating, despite a broader analyst consensus of \"moderate buy\" with a $205.80 price target. Other analysts maintain bullish outlooks, with price targets ranging from $214 to $270. Insiders have sold shares worth approximately $2.99 million in the past 90 days, while the company continues to develop small-molecule treatments for metabolic and inflammatory diseases.", "age_days": 18.1, "is_stale": false, "sentiment": "negative", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/belite-bio-nasdaqblte-stock-rating-lowered-by-zacks-research-2026-08-20", "source_name": "MarketBeat", "published_at": "2026-08-20T11:40:42", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "freshness_pct": 1.5, "sentiment_pct": 43, "evidence_basis": "archived_article", "evidence_share": 0.3, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.001549, "influence_label": "Low", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 29, "published_display": "20 Aug 2026 11:40", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.3"}, {"url": "https://www.reveliolabs.com/companies/belite-bio/employees", "tier": "direct", "title": "Belite Bio Number of Employees 2026 | Employee Count & Headcount Data", "topics": ["Earnings", "Life Sciences"], "summary": "Belite Bio, Inc. (NASDAQ: BLTE) had approximately 50 employees worldwide as of March 2026, representing a 232.6% growth from 2023. The company is actively hiring, with 1 active job posting in 2026, and its workforce is primarily concentrated in North America. The average salary is $151,597, with significant regional variations.", "age_days": 19.2, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.reveliolabs.com/companies/belite-bio/employees", "source_name": "Revelio Labs", "published_at": "2026-08-19T09:10:20", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 7.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.006719, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "19 Aug 2026 09:10", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQZmZHb3dJNlZGTW1aM0dVNVpXZ3F0cXpjYTh0bG9HVmhrMzlJOVRIV0ltOXdrS1F5Z3MzdEx6YTBkVDVNdk41cURNTHhBUXBvWTA1aEFQUkRSeFhaNjRWbzdSQTVnWnZJTGFMbzBFM2dCTHVPTkZTUkRQdUJsWjBMQ3RvZ0E0V0JsT3QzSTlabnZHMm0tdFFvbW1lMnc1WmFjbnAzZ1ZCVGVCSUJLWHoxMXcybVhUU1VKOG1XOV9NVXVrcWp4Y1RpeHJNbkYwc0lZbkxTcGItVW9tY0pXbjBPS3RGNmtnVTV3VnBWVXZDZTlWUUhnZl9lQU1nOUhfOXlf?oc=5", "tier": "direct", "title": "Belite (BLTE) Earnings Brief: EPS Falls Short of Its Estimate on the Day; Market Read: Shares Finish 0.39% Down in the Current Update - Revenue Report", "topics": [], "summary": "", "age_days": 20.3, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQZmZHb3dJNlZGTW1aM0dVNVpXZ3F0cXpjYTh0bG9HVmhrMzlJOVRIV0ltOXdrS1F5Z3MzdEx6YTBkVDVNdk41cURNTHhBUXBvWTA1aEFQUkRSeFhaNjRWbzdSQTVnWnZJTGFMbzBFM2dCTHVPTkZTUkRQdUJsWjBMQ3RvZ0E0V0JsT3QzSTlabnZHMm0tdFFvbW1lMnc1WmFjbnAzZ1ZCVGVCSUJLWHoxMXcybVhUU1VKOG1XOV9NVXVrcWp4Y1RpeHJNbkYwc0lZbkxTcGItVW9tY0pXbjBPS3RGNmtnVTV3VnBWVXZDZTlWUUhnZl9lQU1nOUhfOXlf?oc=5", "source_name": "dars.gov.et", "published_at": "2026-08-18T07:00:00+00:00", "tone_signals": ["Missed expectations"], "company_focus": 1.0, "freshness_pct": 6.0, "sentiment_pct": 25, "evidence_basis": "headline_only", "evidence_share": 2.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.012862, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 52, "published_display": "18 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.1"}, {"url": "https://m.investing.com/news/insider-trading-news/belite-bio-ceo-lin-yuhsin-sells-company-stock-over-65000-93CH-4860272?ampMode=1", "tier": "direct", "title": "Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio CEO Lin Yu-Hsin sold 365 American depositary shares worth over $65,000 on August 12, 2026, as part of a Rule 10b5-1 trading plan. Despite the stock's remarkable 141% return over the past year, shares have recently declined to $166.28 from the transaction price of around $180. Additionally, Belite Bio reported a smaller-than-expected loss for Q2 2026, with an adjusted EPS of -$0.54, exceeding analysts' estimates.", "age_days": 23.7, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://m.investing.com/news/insider-trading-news/belite-bio-ceo-lin-yuhsin-sells-company-stock-over-65000-93CH-4860272?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-14T19:41:05", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "freshness_pct": 3.7, "sentiment_pct": 38, "evidence_basis": "archived_article", "evidence_share": 1.8, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.010966, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 39, "published_display": "14 Aug 2026 19:41", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.8"}, {"url": "https://www.investing.com/news/analyst-ratings/benchmark-reiterates-belite-bio-stock-rating-on-fda-priority-review-93CH-4860741", "tier": "direct", "title": "Benchmark reiterates Belite Bio stock rating on FDA priority review", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Benchmark has reiterated a Buy rating and a $217.00 price target for Belite Bio (NASDAQ:BLTE) after the FDA granted Priority Review to the company's New Drug Application for Tinlarebant, targeting a PDUFA date of February 12, 2027. Belite Bio plans significant R&D and marketing investments for Tinlarebant's commercial launch in Q1 2027 and is well-capitalized with $280 million in cash and $500 million in investments. This follows a smaller-than-expected Q2 2026 loss and a raised price target from Mizuho.", "age_days": 23.8, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.investing.com/news/analyst-ratings/benchmark-reiterates-belite-bio-stock-rating-on-fda-priority-review-93CH-4860741", "source_name": "Investing.com", "published_at": "2026-08-14T19:11:36", "tone_signals": ["Analyst upgrade", "Buy Rating", "Contract or approval won"], "company_focus": 1.0, "freshness_pct": 0.4, "sentiment_pct": 64, "evidence_basis": "archived_article", "evidence_share": 0.2, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.001126, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 38, "published_display": "14 Aug 2026 19:11", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.2"}, {"url": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-blte-stock-looks-151152548.html", "tier": "direct", "title": "Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run", "topics": ["Clinical Trials", "Earnings", "Fda Approval", "Financial Markets", "Life Sciences", "Overvaluation"], "summary": "Belite Bio (BLTE) stock has experienced a significant 431.2% return over the past three years. Despite this impressive performance and regulatory progress for its drug tinlarebant, valuation metrics suggest the stock may be fully priced, trading at a P/B ratio significantly above the industry average. The article suggests that future movements will depend on whether current pricing already accounts for the potential cash generation from its clinical and regulatory milestones.", "age_days": 23.9, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-blte-stock-looks-151152548.html", "source_name": "Simply Wall St.", "published_at": "2026-08-14T15:11:52+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 3.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.003479, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "14 Aug 2026 15:11", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.sahmcapital.com/news/content/belite-bio-blte-could-be-21-below-fair-value-as-fda-priority-review-lands-2026-08-15", "tier": "direct", "title": "Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands", "topics": ["Biotech", "Earnings", "Fda Approval", "Financial Markets", "Intrinsic Value", "Life Sciences"], "summary": "Belite Bio (BLTE) is drawing attention after the FDA granted Priority Review to its New Drug Application for tinlarebant, a Stargardt Disease Type 1 treatment. Despite a recent stock pullback following a quarterly loss, the company is considered undervalued by 21.4% according to analyst targets and its fair value estimate of $211.50, driven by its strong cash position and planned R&D and commercialization investments. However, its valuation also carries uncertainties regarding regulatory decisions and expansion data.", "age_days": 24.0, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.sahmcapital.com/news/content/belite-bio-blte-could-be-21-below-fair-value-as-fda-priority-review-lands-2026-08-15", "source_name": "Sahm", "published_at": "2026-08-14T12:42:17", "tone_signals": ["Contract or approval won", "Positive valuation view"], "company_focus": 1.0, "freshness_pct": 3.6, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 1.1, "score_included": true, "duplicate_count": 4, "evidence_weight": 0.00648, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 33, "published_display": "14 Aug 2026 12:42", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.1"}, {"url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNMG94TkQ0S1pJVjBzRnlKd1V3ZkNMcTVHMkR0YXMyS3lDYzlVR1VfakdiNllBMmJHcXctUWJ1V2NoZXhNQmRhTm4zcVNoWWpfajZGZ0FUY3pZTGtRbVB0RHZCamlIT1hoNTcwOVVYcExFUWZpazFEcVUtTWVuNFBmSmRDZ2lUMnZYOE5LMHZnZUZWTUlvSXJrY2I3MDZ6cnRXcW53cnFoZ0dUejBTd1l1Skt0Tk04M3h3b3MxdmJYeUkxeUNpS2c?oc=5", "tier": "direct", "title": "Mizuho raises Belite Bio stock price target to $220 on NDA progress", "topics": [], "summary": "", "age_days": 24.1, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNMG94TkQ0S1pJVjBzRnlKd1V3ZkNMcTVHMkR0YXMyS3lDYzlVR1VfakdiNllBMmJHcXctUWJ1V2NoZXhNQmRhTm4zcVNoWWpfajZGZ0FUY3pZTGtRbVB0RHZCamlIT1hoNTcwOVVYcExFUWZpazFEcVUtTWVuNFBmSmRDZ2lUMnZYOE5LMHZnZUZWTUlvSXJrY2I3MDZ6cnRXcW53cnFoZ0dUejBTd1l1Skt0Tk04M3h3b3MxdmJYeUkxeUNpS2c?oc=5", "source_name": "Investing.com India", "published_at": "2026-08-14T11:30:09+00:00", "tone_signals": ["Analyst upgrade"], "company_focus": 1.0, "freshness_pct": 0.4, "sentiment_pct": 69, "evidence_basis": "headline_only", "evidence_share": 0.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000777, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 42, "published_display": "14 Aug 2026 11:30", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.1"}, {"url": "https://www.marketscreener.com/news/mizuho-adjusts-price-target-on-belite-bio-to-220-from-215-maintains-outperform-rating-ce7859dede8ef526", "tier": "direct", "title": "Mizuho Adjusts Price Target on Belite Bio to $220 From $215, Maintains Outperform Rating", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Mizuho has increased its price target for Belite Bio (NASDAQ:BLTE) to $220 from $215, while reaffirming an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm. The biopharmaceutical company is focused on developing novel therapeutics for retinal degenerative eye diseases and metabolic conditions.", "age_days": 24.1, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/mizuho-adjusts-price-target-on-belite-bio-to-220-from-215-maintains-outperform-rating-ce7859dede8ef526", "source_name": "www.marketscreener.com", "published_at": "2026-08-14T11:12:55", "tone_signals": ["Analyst upgrade"], "company_focus": 1.0, "freshness_pct": 0.4, "sentiment_pct": 67, "evidence_basis": "archived_article", "evidence_share": 0.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000676, "influence_label": "Medium", "event_confidence": 93, "company_focus_pct": 100, "evidence_strength": 40, "published_display": "14 Aug 2026 11:12", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.1"}, {"url": "https://www.marketbeat.com/instant-alerts/yu-hsin-lin-sells-365-shares-of-belite-bio-nasdaqblte-stock-2026-08-14", "tier": "direct", "title": "Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio CEO Yu-Hsin Lin sold 365 shares of the company's stock for a total of $65,827.75, reducing his ownership by 0.21%. Despite the sale, analyst sentiment remains largely positive with a \"Moderate Buy\" consensus and a target price of $204.40, especially following the FDA's priority review of tinlarebant. However, Belite Bio remains a clinical-stage company reporting ongoing losses, making its valuation dependent on regulatory decisions and clinical success.", "age_days": 24.1, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/yu-hsin-lin-sells-365-shares-of-belite-bio-nasdaqblte-stock-2026-08-14", "source_name": "MarketBeat", "published_at": "2026-08-14T11:12:55", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "freshness_pct": 3.5, "sentiment_pct": 40, "evidence_basis": "archived_article", "evidence_share": 1.2, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.007045, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 36, "published_display": "14 Aug 2026 11:12", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.2"}, {"url": "https://finance.yahoo.com/healthcare/articles/belite-bio-inc-blte-q2-070022030.html", "tier": "direct", "title": "Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...", "topics": ["Clinical Trials", "Earnings", "Fda Approval", "Pharma", "Rare Diseases"], "summary": "This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant with Priority Review, establishing a PDUFA date of February 12, 2027. New secondary endpoint data from the Phase 3 DRAGON study presented at ASRS showed that Tinlarabant halted or slightly decreased QAF values (by ~2%) at month 25, compared to a ~20% increase in the placebo group. The company is initiating ", "age_days": 24.3, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/belite-bio-inc-blte-q2-070022030.html", "source_name": "GuruFocus.com", "published_at": "2026-08-14T07:00:22+00:00", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 3.5, "sentiment_pct": 59, "evidence_basis": "headline_only", "evidence_share": 0.8, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.005036, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 33, "published_display": "14 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.8"}, {"url": "https://m.investing.com/news/transcripts/earnings-call-transcript-belite-bio-beats-q2-2026-eps-view-as-stock-slips-93CH-4859329?ampMode=1", "tier": "direct", "title": "Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips", "topics": ["Clinical Trials", "Earnings", "Fda Approval", "Life Sciences", "Pharma", "Rare Diseases"], "summary": "Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A expenses in preparation for commercialization, Belite Bio maintains a strong cash balance of $780 million to fund future operations and development.", "age_days": 24.7, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://m.investing.com/news/transcripts/earnings-call-transcript-belite-bio-beats-q2-2026-eps-view-as-stock-slips-93CH-4859329?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-13T21:40:51", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "freshness_pct": 3.3, "sentiment_pct": 75, "evidence_basis": "archived_article", "evidence_share": 2.2, "score_included": true, "duplicate_count": 5, "evidence_weight": 0.013396, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 52, "published_display": "13 Aug 2026 21:40", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.2"}, {"url": "https://www.sahmcapital.com/news/content/belite-bio-blte-is-up-129-after-fda-priority-review-for-tinlarebant-in-stargardt-disease-2026-08-13", "tier": "direct", "title": "Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease", "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "Earnings", "FDA-APPROVAL"], "summary": "Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. The PDUFA target action date is set for February 12, 2027, and if approved, tinlarebant would be the first FDA-approved treatment for this rare retinal disease. This development significantly sharpens Belite Bio's investment narrative, moving it from clinical execution to regulatory resolution, with potential revenue projections of $563.2 million and earnings of $318.3 million by 2029.", "age_days": 24.7, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.sahmcapital.com/news/content/belite-bio-blte-is-up-129-after-fda-priority-review-for-tinlarebant-in-stargardt-disease-2026-08-13", "source_name": "Sahm", "published_at": "2026-08-13T19:41:05", "tone_signals": ["Contract or approval won", "Institutional or insider buying"], "company_focus": 0.78, "freshness_pct": 3.2, "sentiment_pct": 58, "evidence_basis": "archived_article", "evidence_share": 0.8, "score_included": true, "duplicate_count": 4, "evidence_weight": 0.004621, "influence_label": "Low", "event_confidence": 61, "company_focus_pct": 78, "evidence_strength": 30, "published_display": "13 Aug 2026 19:41", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0.8"}, {"url": "https://www.marketbeat.com/instant-alerts/belite-bio-nasdaqblte-stock-price-down-72-should-you-sell-2026-08-13", "tier": "direct", "title": "Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Should You Sell?", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio (NASDAQ:BLTE) stock declined 7.2% to $166.11 on Thursday, with trading volume below its average. Despite the drop, analysts have a \"Moderate Buy\" consensus rating with an average price target of $204.40. The company, a clinical-stage biotechnology firm, reported a narrower-than-expected quarterly loss of $0.54 per share.", "age_days": 24.7, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/belite-bio-nasdaqblte-stock-price-down-72-should-you-sell-2026-08-13", "source_name": "MarketBeat", "published_at": "2026-08-13T19:40:51", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 3.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.003504, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 19:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOd3FyZE8xYVdZS2hjN253cTd4cXRJTjNpWm1Zbm5mQWVIbGE4c3c2YjM5eTRscnA1TmlVX0VjS1o2NGdzVU42bndhY2RCSm41d1Z5Yk43R0I2VlR3TTFuRjd1c3U2Wkh6NEl6US1FVGJPbEgtQlhMS0gzS2t4amlieFhFdnU2QTU3dWV6WkVXZzN2aDRPZzNHaEg4MDVZX1VCYWxYbHFhR3hkX2xtbjN5T2xJME9rNEVpUTVnQzdaYWhSS01HQUEwZUo2UTlMcU1M?oc=5", "tier": "direct", "title": "Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS", "topics": [], "summary": "", "age_days": 24.8, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOd3FyZE8xYVdZS2hjN253cTd4cXRJTjNpWm1Zbm5mQWVIbGE4c3c2YjM5eTRscnA1TmlVX0VjS1o2NGdzVU42bndhY2RCSm41d1Z5Yk43R0I2VlR3TTFuRjd1c3U2Wkh6NEl6US1FVGJPbEgtQlhMS0gzS2t4amlieFhFdnU2QTU3dWV6WkVXZzN2aDRPZzNHaEg4MDVZX1VCYWxYbHFhR3hkX2xtbjN5T2xJME9rNEVpUTVnQzdaYWhSS01HQUEwZUo2UTlMcU1M?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-13T18:34:44+00:00", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "freshness_pct": 3.2, "sentiment_pct": 75, "evidence_basis": "headline_only", "evidence_share": 1.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.006876, "influence_label": "Medium", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 51, "published_display": "13 Aug 2026 18:34", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.1"}, {"url": "https://glance.eyesoneyecare.com/stories/2026-08-12/fda-accepts-belite-s-tinlarebant-nda-for-stargardt", "tier": "direct", "title": "FDA accepts Belite's tinlarebant NDA for Stargardt", "topics": ["Life Sciences"], "summary": "Belite Bio, Inc. has received FDA acceptance for its new drug application (NDA) for tinlarebant, an investigational therapy for Stargardt disease type 1 (STGD1). The FDA has granted tinlarebant a priority review, setting the PDUFA target action date for February 12, 2027. If approved, tinlarebant would be the first-ever treatment for STGD1.", "age_days": 25.0, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://glance.eyesoneyecare.com/stories/2026-08-12/fda-accepts-belite-s-tinlarebant-nda-for-stargardt", "source_name": "Glance by Eyes On Eyecare", "published_at": "2026-08-13T12:42:17", "tone_signals": ["Contract or approval won"], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 1.7e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 12:42", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.nasdaq.com/articles/belite-bio-q2-net-loss-widens-fda-sets-pdufa-date-tinlarebant-february-2027", "tier": "direct", "title": "Belite Bio Q2 Net Loss Widens; FDA Sets PDUFA Date For Tinlarebant In February 2027", "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Financial Results"], "summary": "(RTTNews) - Belite Bio, Inc (BLTE), a clinical-stage drug development company, announced its financial results for the second quarter, reflecting a wider net loss. The company also provided an update on its New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1), an inherited macular dystrophy condition. Company Profile Belite Bio focuses on degenerative retinal diseases such as Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio's lead can", "age_days": 25.2, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.nasdaq.com/articles/belite-bio-q2-net-loss-widens-fda-sets-pdufa-date-tinlarebant-february-2027", "source_name": "nasdaq.com", "published_at": "2026-08-13T09:42:05+00:00", "tone_signals": ["Loss widened"], "company_focus": 0.78, "freshness_pct": 3.1, "sentiment_pct": 30, "evidence_basis": "archived_article", "evidence_share": 0.7, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.0045, "influence_label": "Medium", "event_confidence": 69, "company_focus_pct": 78, "evidence_strength": 42, "published_display": "13 Aug 2026 09:42", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0.7"}, {"url": "https://www.stocktitan.net/sec-filings/BLTE/6-k-belite-bio-inc-current-report-foreign-issuer-f8d7b1bcd4d1.html", "tier": "direct", "title": "Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss", "topics": ["Earnings", "Life Sciences"], "summary": "Belite Bio announced that the FDA accepted its New Drug Application for tinlarebant with Priority Review for treating Stargardt disease type 1, setting a PDUFA target action date of February 12, 2027. Despite this regulatory progress, the company reported a wider net loss of $28.4 million for Q2 2026, up from $16.3 million a year prior, due to increased R&D and SG&A expenses as it prepares for tinlarebant's potential launch. Belite Bio maintains strong liquidity with $279.9 million in cash and equivalents and $500.1 million in U.S. treasury investments.", "age_days": 25.2, "is_stale": false, "sentiment": "negative", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/BLTE/6-k-belite-bio-inc-current-report-foreign-issuer-f8d7b1bcd4d1.html", "source_name": "Stock Titan", "published_at": "2026-08-13T09:40:51", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 8.3, "sentiment_pct": 43, "evidence_basis": "archived_article", "evidence_share": 2.1, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.012507, "influence_label": "Low", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 32, "published_display": "13 Aug 2026 09:40", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.1"}, {"url": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-q2-non-gaap-073955534.html", "tier": "direct", "title": "Belite Bio Q2 Non-GAAP Net Loss Widens", "topics": [], "summary": "", "age_days": 25.2, "is_stale": false, "sentiment": "negative", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-q2-non-gaap-073955534.html", "source_name": "MT Newswires", "published_at": "2026-08-13T07:39:55+00:00", "tone_signals": ["Loss widened"], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 32, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 1.9e-05, "influence_label": "Medium", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 41, "published_display": "13 Aug 2026 07:39", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1"}, {"url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOYzE2eXItYXV3Njh6dmlCaGU4X0VXLXdoaWdMdzVIUjVoQTVlb0FsZEVOc1d3YnU4bXlyUHFpb1ZzcHAwMkN5UlpET2JEUG9Ed19FNWFZYnBPMDlpcTg3QnZIcXFGTkxRNy14dGxhWExVbllmVDhFSmhlSE9sYXlhdzZla1R4RVd3SEFyZm9BcG45VmttdWxxeE83T1E1d2FLOE1aVVBtcVBfSHBVbXJBQVFWR0JyTGdH?oc=5", "tier": "direct", "title": "Belite Bio will give a second-quarter business update Aug. 13", "topics": [], "summary": "", "age_days": 25.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOYzE2eXItYXV3Njh6dmlCaGU4X0VXLXdoaWdMdzVIUjVoQTVlb0FsZEVOc1d3YnU4bXlyUHFpb1ZzcHAwMkN5UlpET2JEUG9Ed19FNWFZYnBPMDlpcTg3QnZIcXFGTkxRNy14dGxhWExVbllmVDhFSmhlSE9sYXlhdzZla1R4RVd3SEFyZm9BcG45VmttdWxxeE83T1E1d2FLOE1aVVBtcVBfSHBVbXJBQVFWR0JyTGdH?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-13T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 8e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/belite-bio-reports-unaudited-second-014500110.html", "tier": "direct", "title": "Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update", "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "Earnings", "FDA-APPROVAL"], "summary": "Belite Bio announced its second-quarter 2026 financial results, highlighting significant progress in the development of tinlarebant for Stargardt disease type 1 (STGD1), including the FDA's acceptance of its New Drug Application with Priority Review. The company reported increased R&D and SG&A expenses due to milestone payments, manufacturing, and team expansion, resulting in a net loss of $28.4 million for the quarter. Belite Bio also provided updates on its DRAGON II and PHOENIX trials and ongoing commercialization preparations.", "age_days": 25.5, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/belite-bio-reports-unaudited-second-014500110.html", "source_name": "GlobeNewswire", "published_at": "2026-08-13T01:45:00+00:00", "tone_signals": ["Negative financial language"], "company_focus": 0.78, "freshness_pct": 2.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.002739, "influence_label": "None", "event_confidence": 69, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "13 Aug 2026 01:45", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/blte-stock-rises-fda-grants-125400613.html", "tier": "direct", "title": "BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA", "topics": ["Biotech", "Clinical Trials", "Earnings", "Earnings Per Share", "Fda Approval", "Growth Rate"], "summary": "Belite Bio BLTE announced that the FDA has accepted the new drug application (NDA) seeking approval for its lead candidate, tinlarebant, for the treatment of patients with Stargardt Disease type I (STGD1). With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on Feb. 12, 2027. Shares rose around 6.2% on Tuesday following the announcement. A priority review designation means the FDA's goal is to take action on an application within six months compared with 10 months under standard review. If approved, tinlarebant would become the first FDA-approved ", "age_days": 26.0, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/blte-stock-rises-fda-grants-125400613.html", "source_name": "Zacks", "published_at": "2026-08-12T12:54:00+00:00", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "freshness_pct": 2.7, "sentiment_pct": 72, "evidence_basis": "archived_article", "evidence_share": 1.1, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.006396, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 45, "published_display": "12 Aug 2026 12:54", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "1.1"}, {"url": "https://m.investing.com/news/analyst-ratings/belite-bio-stock-price-target-raised-to-214-by-hc-wainwright-on-fda-review-93CH-4854826?ampMode=1", "tier": "direct", "title": "Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "H.C. Wainwright has increased its price target for Belite Bio (NASDAQ:BLTE) to $214 from $200, maintaining a Buy rating, after the FDA granted Priority Review to the New Drug Application for tinlarebant, a treatment for Stargardt disease type 1. The drug, which has shown significant reduction in retinal lesion growth in trials, has also received Breakthrough Therapy and Orphan Drug designations. The FDA is set to make a decision by February 12, 2027, and Belite Bio is expected to report Q2 2026 results soon.", "age_days": 26.1, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://m.investing.com/news/analyst-ratings/belite-bio-stock-price-target-raised-to-214-by-hc-wainwright-on-fda-review-93CH-4854826?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-12T12:11:21", "tone_signals": ["Analyst upgrade", "Buy Rating", "Contract or approval won"], "company_focus": 1.0, "freshness_pct": 0.2, "sentiment_pct": 80, "evidence_basis": "archived_article", "evidence_share": 0.2, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.000965, "influence_label": "Medium", "event_confidence": 85, "company_focus_pct": 100, "evidence_strength": 55, "published_display": "12 Aug 2026 12:11", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.2"}, {"url": "https://seekingalpha.com/news/4631365-belite-bio-lead-asset-granted-fda-priority-review", "tier": "direct", "title": "Belite Bio lead asset granted FDA priority review (BLTE:NASDAQ)", "topics": ["Financial Markets", "Life Sciences"], "summary": "The FDA has accepted Belite Bio's marketing application for its lead asset, tinlarebant, granting it priority review. This therapy targets an eye disease, and the FDA has set a target action date of February 12, 2027.", "age_days": 26.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://seekingalpha.com/news/4631365-belite-bio-lead-asset-granted-fda-priority-review", "source_name": "Seeking Alpha", "published_at": "2026-08-12T11:11:21", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 9e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 11:11", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/belite-bio-announces-u-food-200100791.html", "tier": "direct", "title": "Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1", "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Growth Rate", "Life Sciences", "Pharma"], "summary": "Belite Bio announced that the FDA has accepted and granted Priority Review for its New Drug Application (NDA) for tinlarebant, aimed at treating Stargardt Disease Type 1 (STGD1). The FDA set a PDUFA date of February 12, 2027, and if approved, tinlarebant would be the first-ever treatment for this rare, inherited retinal disease. The NDA is supported by positive results from the Phase 3 DRAGON trial, showing a significant reduction in the growth rate of atrophic retinal lesions.", "age_days": 26.7, "is_stale": false, "sentiment": "positive", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/belite-bio-announces-u-food-200100791.html", "source_name": "Market source", "published_at": "2026-08-11T19:45:16", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "freshness_pct": 7.1, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 1.5, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.009297, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 30, "published_display": "11 Aug 2026 19:45", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "1.5"}, {"url": "https://www.marketbeat.com/instant-alerts/belite-bio-inc-sponsored-adr-nasdaqblte-receives-average-rating-of-moderate-buy-from-brokerages-2026-08-09", "tier": "direct", "title": "Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of \"Moderate Buy\" from Brokerages", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) has received a consensus \"Moderate Buy\" rating from brokerages, with an average 12-month price target of $203.00. The company recently reported a quarterly loss of $0.34 per share, beating analyst estimates. Despite an insider selling 10,000 shares, institutional ownership remains limited.", "age_days": 28.6, "is_stale": false, "sentiment": "neutral", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/belite-bio-inc-sponsored-adr-nasdaqblte-receives-average-rating-of-moderate-buy-from-brokerages-2026-08-09", "source_name": "MarketBeat", "published_at": "2026-08-09T23:11:21", "tone_signals": ["Negative financial language"], "company_focus": 0.78, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 8.9e-05, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "09 Aug 2026 23:11", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.stocktradersdaily.com/news_release/1/How_Belite_Bio_Inc_BLTE_Affects_Rotational_Strategy_Timing_080926065202_1786272722.html", "tier": "direct", "title": "How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing", "topics": ["Financial Markets", "Life Sciences"], "summary": "This article analyzes Belite Bio Inc (BLTE) and its impact on rotational trading strategies. It highlights strong sentiment supporting an overweight bias, an exceptional risk-reward setup, and provides details on various institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.", "age_days": 29.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.stocktradersdaily.com/news_release/1/How_Belite_Bio_Inc_BLTE_Affects_Rotational_Strategy_Timing_080926065202_1786272722.html", "source_name": "Stock Traders Daily", "published_at": "2026-08-09T06:52:00", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 54, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 3e-06, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Aug 2026 06:52", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://www.marketscreener.com/news/belite-bio-shares-rise-after-canaccord-initiates-coverage-with-buy-rating-ce785bdbd980f126", "tier": "direct", "title": "Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio's shares rose after Canaccord Genuity initiated coverage with a Buy rating and a $303 price target. This positive analyst coverage comes amidst other recent news for Belite Bio, including FDA Priority Review for its Stargardt Disease treatment, Tinlarebant. The company is focused on developing therapeutics for retinal degenerative eye diseases and metabolic conditions.", "age_days": 2.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "214493a9b79a29ed46dd8a05b11b114bc213f7b346f5e7bdab7fda5165053b5f", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/belite-bio-shares-rise-after-canaccord-initiates-coverage-with-buy-rating-ce785bdbd980f126", "source_name": "marketscreener.com", "published_at": "2026-09-04T19:40:09", "source_names": ["marketscreener.com"], "target_scope": "Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating Belite Bio's shares rose after Canaccord Genuity initiated coverage with a Buy rating and a $303 price target. This positive analyst coverage comes amidst other recent news for Belite Bio, including FDA Priority Review for its Stargardt Disease treatment, Tinlarebant.", "tone_signals": ["Analyst upgrade"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 53.0, "sentiment_pct": 75, "evidence_basis": "archived_article", "evidence_share": 15.8, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.095502, "influence_label": "High", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.695, "provider_symbols": ["BLTE", "BLTE.ARCHIVE", "CF.TO"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 58, "published_display": "04 Sep 2026 19:40", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "15.8", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.4583}, {"url": "https://finance.yahoo.com/healthcare/articles/belite-bio-apos-tinlarebant-revenue-153246252.html", "tier": "direct", "title": "Belite Bio's Tinlarebant Revenue Estimates Have Multiple Drivers of Upside, Mizuho Says", "topics": [], "summary": "", "age_days": 2.9, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "positive", "story_key": "d82c445d8fb61865ad91a91c776b13d38891263d36af579d23882dd79be52f50", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/belite-bio-apos-tinlarebant-revenue-153246252.html", "source_name": "MT Newswires", "published_at": "2026-09-04T15:45:37+00:00", "source_names": ["MT Newswires"], "target_scope": "Belite Bio's Tinlarebant Revenue Estimates Have Multiple Drivers of Upside, Mizuho Says", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 66.8, "sentiment_pct": 57, "evidence_basis": "headline_only", "evidence_share": 12.6, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.076222, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.461, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 45, "published_display": "04 Sep 2026 15:45", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "12.6", "target_provider_symbol": "BLTE", "provider_directional_mass": null}, {"url": "https://m.investing.com/news/analyst-ratings/canaccord-initiates-belite-bio-stock-with-buy-on-stargardt-therapy-93CH-4889421?ampMode=1", "tier": "direct", "title": "Canaccord initiates Belite Bio stock with buy on Stargardt therapy", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Canaccord Genuity initiated coverage on Belite Bio, Inc, ADR (NASDAQ:BLTE) with a buy rating and a $303 price target, citing optimism for its Stargardt disease therapy, Tinlarebant. The drug has shown significant efficacy in trials and has an FDA PDUFA date set for February 12, 2027. Belite Bio also reported a smaller-than-expected loss for Q2 2026 and possesses strong liquidity to fund its U.S. launch.", "age_days": 3.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "658c0a235e8a672046ca7fab6845405571f0af93df442a7398a0d47e59329a43", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://m.investing.com/news/analyst-ratings/canaccord-initiates-belite-bio-stock-with-buy-on-stargardt-therapy-93CH-4889421?ampMode=1", "source_name": "Investing.com", "published_at": "2026-09-04T11:40:09", "source_names": ["Investing.com"], "target_scope": "Canaccord initiates Belite Bio stock with buy on Stargardt therapy Canaccord Genuity initiated coverage on Belite Bio, Inc, ADR (NASDAQ:BLTE) with a buy rating and a $303 price target, citing optimism for its Stargardt disease therapy, Tinlarebant. Belite Bio also reported a smaller-than-expected loss for Q2 2026 and possesses strong liquidity to fund its U.S.", "tone_signals": ["Analyst upgrade", "Buy Rating"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 49.1, "sentiment_pct": 74, "evidence_basis": "archived_article", "evidence_share": 25.4, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.15375, "influence_label": "High", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.699, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 60, "published_display": "04 Sep 2026 11:40", "direction_included": true, "sentiment_conflict": 0.071, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "25.4", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.8174}, {"url": "https://finance.yahoo.com/markets/stocks/articles/canaccord-genuity-initiates-belite-bio-095227716.html", "tier": "direct", "title": "Canaccord Genuity Initiates Belite Bio at Buy With $303 Price Target", "topics": [], "summary": "", "age_days": 3.2, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "positive", "story_key": "7db4d7f4c16d6ea87a64465cb96ed15a5c37b0e1c0a35976698ca7241e5dc2d7", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/canaccord-genuity-initiates-belite-bio-095227716.html", "source_name": "MT Newswires", "published_at": "2026-09-04T09:52:27+00:00", "source_names": ["MT Newswires"], "target_scope": "Canaccord Genuity Initiates Belite Bio at Buy With $303 Price Target", "tone_signals": ["Analyst upgrade"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 48.3, "sentiment_pct": 69, "evidence_basis": "headline_only", "evidence_share": 11.8, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.071611, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.57, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 53, "published_display": "04 Sep 2026 09:52", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "11.8", "target_provider_symbol": "BLTE", "provider_directional_mass": null}, {"url": "https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-belite-bio-stock-rating-on-commercial-plans-93CH-4887644?ampMode=1", "tier": "direct", "title": "H.C. Wainwright reiterates Belite Bio stock rating on commercial plans", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "H.C. Wainwright has reiterated a Buy rating and a $214 price target for Belite Bio (NASDAQ:BLTE) due to its commercial plans for tinlarebant, a Stargardt disease treatment. The company aims for a March 2027 launch, pending FDA approval, and has outlined a comprehensive commercial strategy with a strong balance sheet to support it. Belite Bio also reported better-than-expected Q2 2026 earnings and received Priority Review for its New Drug Application.", "age_days": 3.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "4ee94a74d0f4f9f0026a8d186f1aee687d989616105bcf50551a66577a7e6403", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-belite-bio-stock-rating-on-commercial-plans-93CH-4887644?ampMode=1", "source_name": "Investing.com", "published_at": "2026-09-03T20:40:09", "source_names": ["Investing.com"], "target_scope": "Wainwright reiterates Belite Bio stock rating on commercial plans Wainwright has reiterated a Buy rating and a $214 price target for Belite Bio (NASDAQ:BLTE) due to its commercial plans for tinlarebant, a Stargardt disease treatment. Belite Bio also reported better-than-expected Q2 2026 earnings and received Priority Review for its New Drug Application.", "tone_signals": ["Fda Approval", "Buy Rating"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 42.5, "sentiment_pct": 64, "evidence_basis": "archived_article", "evidence_share": 17.1, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.103902, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.659, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 48, "published_display": "03 Sep 2026 20:40", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "17.1", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.4135}, {"url": "https://finance.yahoo.com/m/2cb87858-4af2-3f04-85fa-20d62548d58e/belite-bio-wins-fda-priority.html", "tier": "direct", "title": "Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease", "topics": ["Finance", "Financial Markets", "Life Sciences"], "summary": "Belite Bio has received FDA Priority Review for its new drug application for tinlarebant to treat Stargardt disease type 1, with a PDUFA date set for February 12, 2027. If approved, tinlarebant would be the first treatment for this rare inherited retinal disease, having shown a 35.7% reduction in retinal lesion growth in Phase III trials. The company is actively preparing for commercial launch, including building sales infrastructure, physician education programs, and patient support services, targeting an estimated 53,000 U.S. patients.", "age_days": 4.4, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "neutral", "story_key": "8feeb1205c1198cbf109ad1c9fda272ab6547354695f7dd84fe3ff53022bdd3c", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/2cb87858-4af2-3f04-85fa-20d62548d58e/belite-bio-wins-fda-priority.html", "source_name": "MarketBeat", "published_at": "2026-09-03T04:01:58+00:00", "source_names": ["MarketBeat"], "target_scope": "Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease Belite Bio has received FDA Priority Review for its new drug application for tinlarebant to treat Stargardt disease type 1, with a PDUFA date set for February 12, 2027.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 21.8, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.010422, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BLTE", "BLTE.ARCHIVE", "COIN"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "03 Sep 2026 04:01", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": null}, {"url": "https://www.marketscreener.com/news/belite-bio-to-participate-in-four-upcoming-investor-conferences-ce7858ddd18df321", "tier": "direct", "title": "Belite Bio to Participate in Four Upcoming Investor Conferences", "topics": ["Clinical Trials", "Finance", "Healthcare", "Life Sciences", "Retinal Diseases"], "summary": "Belite Bio, Inc (NASDAQ: BLTE) announced its participation in four upcoming investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference, 2026 Cantor Global Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The company, a clinical-stage drug developer focusing on degenerative retinal diseases, will present at these events through fireside chats. Webcasts of these presentations will be available on Belite Bio's investor relations website for 90 days.", "age_days": 6.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "139777c6b040fd803a3913e6e4b10a45831346a6fe204a616619fc59e259022c", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/belite-bio-to-participate-in-four-upcoming-investor-conferences-ce7858ddd18df321", "source_name": "www.marketscreener.com", "published_at": "2026-09-01T12:19:45", "source_names": ["www.marketscreener.com"], "target_scope": "Belite Bio to Participate in Four Upcoming Investor Conferences Belite Bio, Inc (NASDAQ: BLTE) announced its participation in four upcoming investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference, 2026 Cantor Global Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and H.C. Webcasts of these presentations will be available on Belite Bio's investor relations website for 90 days.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 12.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "durable_archive": false, "evidence_weight": 0.007662, "influence_label": "None", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BLTE", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "01 Sep 2026 12:19", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.3164}, {"url": "https://www.stocktitan.net/news/BLTE/belite-bio-to-host-virtual-commercial-day-on-september-2-pdcyu0o78vgf.html", "tier": "direct", "title": "The FDA set Feb. 12, 2027, for reviewing a Stargardt disease drug", "topics": ["Earnings", "Life Sciences"], "summary": "Belite Bio (NASDAQ: BLTE) will host a Virtual Commercial Day on September 2, 2026, to discuss its lead candidate, tinlarebant, for Stargardt disease type 1 (STGD1). The FDA has granted Priority Review for tinlarebant's New Drug Application, with a Prescription Drug User Fee Act (PDUFA) date set for February 12, 2027. The event will feature management, ophthalmology experts, and patients, covering disease overview, unmet needs, treatment landscape, and commercial opportunities if the drug is approved.", "age_days": 13.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "1b1f283ac8c94fe336f7005da02dbf13b6a5f480dbad14a6d928d49a92d6ba1e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/news/BLTE/belite-bio-to-host-virtual-commercial-day-on-september-2-pdcyu0o78vgf.html", "source_name": "Stock Titan", "published_at": "2026-08-24T20:14:47", "source_names": ["Stock Titan"], "target_scope": "Belite Bio (NASDAQ: BLTE) will host a Virtual Commercial Day on September 2, 2026, to discuss its lead candidate, tinlarebant, for Stargardt disease type 1 (STGD1).", "tone_signals": ["Contract or approval won"], "company_focus": 0.86, "cross_listing": false, "entity_mapped": true, "freshness_pct": 14.9, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.018853, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.533, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 86, "evidence_strength": 0, "published_display": "24 Aug 2026 20:14", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Company discussed", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.3475}, {"url": "https://markets.businessinsider.com/news/stocks/belite-bio-to-host-virtual-commercial-day-on-september-2-2026-1036487980", "tier": "direct", "title": "Belite Bio to Host Virtual Commercial Day on September 2, 2026", "topics": ["Clinical Trials", "Fda Approval", "Finance", "Life Sciences", "Ophthalmology"], "summary": "Belite Bio will host a Virtual Commercial Day on September 2, 2026, to discuss Stargardt disease type 1 (STGD1), unmet medical needs, and the commercial opportunity for their drug tinlarebant. The event will feature Belite Bio's management, ophthalmology experts, and individuals with STGD1, following the FDA's recent acceptance and Priority Review designation for tinlarebant's New Drug Application. The FDA has set a Prescription Drug User Fee Act date of February 12, 2027.", "age_days": 13.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "6529b79e776ddeb78dd02ab92151cb54f03031d55d43dbd08469167bbf65b51c", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "publisher", "source_link": "https://markets.businessinsider.com/news/stocks/belite-bio-to-host-virtual-commercial-day-on-september-2-2026-1036487980", "source_name": "markets.businessinsider.com", "published_at": "2026-08-24T20:14:47", "source_names": ["markets.businessinsider.com"], "target_scope": "Belite Bio to Host Virtual Commercial Day on September 2, 2026 Belite Bio will host a Virtual Commercial Day on September 2, 2026, to discuss Stargardt disease type 1 (STGD1), unmet medical needs, and the commercial opportunity for their drug tinlarebant. The event will feature Belite Bio's management, ophthalmology experts, and individuals with STGD1, following the FDA's recent acceptance and Priority Review designation for tinlarebant's New Drug Application.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 25.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 3, "durable_archive": false, "evidence_weight": 0.021751, "influence_label": "None", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["AMD.US", "BLTE", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "24 Aug 2026 20:14", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.3425}, {"url": "https://www.stocktitan.net/news/BLTE/belite-bio-announces-oral-presentations-at-two-upcoming-medical-13ib6bj138hv.html", "tier": "direct", "title": "Belite Bio sets four talks at two medical meetings, including Phase 3 data", "topics": ["Life Sciences"], "summary": "Belite Bio (NASDAQ: BLTE) announced that data from its Phase 3 DRAGON study of tinlarebant for Stargardt disease will be presented at two major ophthalmology meetings in August 2026: the SOG Annual Congress in Lausanne and the APVRS Congress in Gold Coast. The presentations will include results from the Phase 3 DRAGON study in adolescent and adult Stargardt disease, new insights, and updates on ABCA4-retinopathy therapy trials in Japan. Tinlarebant is a novel oral therapy aimed at reducing bisretinoid accumulation, which causes retinal disease.", "age_days": 16.9, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "bc3ae4e385288047c6647caa1c67c0a58f7ed867b70a22ebb2e1d942314fd873", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/news/BLTE/belite-bio-announces-oral-presentations-at-two-upcoming-medical-13ib6bj138hv.html", "source_name": "Stock Titan", "published_at": "2026-08-21T15:10:46", "source_names": ["Stock Titan"], "target_scope": "Belite Bio sets four talks at two medical meetings, including Phase 3 data Belite Bio (NASDAQ: BLTE) announced that data from its Phase 3 DRAGON study of tinlarebant for Stargardt disease will be presented at two major ophthalmology meetings in August 2026: the SOG Annual Congress in Lausanne and the APVRS Congress in Gold Coast.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000176, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Aug 2026 15:10", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.3835}, {"url": "https://www.globenewswire.com/de/news-release/2026/08/21/3349036/0/en/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences.html", "tier": "direct", "title": "Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences", "topics": ["Clinical Trials", "Life Sciences", "Novel Therapeutics", "Ophthalmology", "Stargardt Disease"], "summary": "Belite Bio, Inc. (NASDAQ: BLTE) will present data from its clinical trials at two upcoming medical conferences: the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress. The presentations will focus on results from the Phase 3 DRAGON study of tinlarebant for adolescent and adult Stargardt Disease. Tinlarebant is an oral therapy designed to reduce vitamin A-based toxins associated with degenerative retinal diseases.", "age_days": 16.9, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "eff90f7b93c2ddcf214defb86004604bc67e758d38d55ad171a077ec62f67f1c", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/de/news-release/2026/08/21/3349036/0/en/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences.html", "source_name": "GlobeNewswire", "published_at": "2026-08-21T15:10:46", "source_names": ["GlobeNewswire"], "target_scope": "Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences Belite Bio, Inc. (NASDAQ: BLTE) will present data from its clinical trials at two upcoming medical conferences: the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress.", "tone_signals": ["Negative financial language"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 4, "durable_archive": false, "evidence_weight": 0.000172, "influence_label": "None", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.45, "provider_symbols": ["AMD.US", "BLTE", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "21 Aug 2026 15:10", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.495}, {"url": "https://www.quiverquant.com/news/Belite+Bio+Announces+Tinlarebant+Data+Presentations+at+SOG+and+APVRS+Congresses", "tier": "direct", "title": "Belite Bio Announces Tinlarebant Data Presentations at SOG and APVRS Congresses", "topics": ["Earnings", "Life Sciences"], "summary": "Belite Bio, Inc. (NASDAQ: BLTE) will present data on its lead therapy, tinlarebant, at two upcoming ophthalmology congresses in Switzerland and Australia. The presentations will focus on the results from the Phase 3 Dragon Study, which evaluated tinlarebant for treating Stargardt disease, an inherited macular dystrophy with no approved treatments. Tinlarebant works by reducing toxic bisretinoid accumulation in the retina and has received several designations to expedite its development.", "age_days": 17.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "30e044aedac118a877aee5a12fb4fef9f74f88303faeaf60a86caccf6d44e027", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.quiverquant.com/news/Belite+Bio+Announces+Tinlarebant+Data+Presentations+at+SOG+and+APVRS+Congresses", "source_name": "Quiver Quantitative", "published_at": "2026-08-21T12:12:00", "source_names": ["Quiver Quantitative"], "target_scope": "Belite Bio Announces Tinlarebant Data Presentations at SOG and APVRS Congresses Belite Bio, Inc. (NASDAQ: BLTE) will present data on its lead therapy, tinlarebant, at two upcoming ophthalmology congresses in Switzerland and Australia.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 9.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.009023, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Aug 2026 12:12", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.2822}, {"url": "https://www.marketbeat.com/instant-alerts/belite-bio-nasdaqblte-stock-rating-lowered-by-zacks-research-2026-08-20", "tier": "direct", "title": "Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Zacks Research", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Zacks Research has downgraded Belite Bio (NASDAQ:BLTE) from a \"strong buy\" to a \"hold\" rating, despite a broader analyst consensus of \"moderate buy\" with a $205.80 price target. Other analysts maintain bullish outlooks, with price targets ranging from $214 to $270. Insiders have sold shares worth approximately $2.99 million in the past 90 days, while the company continues to develop small-molecule treatments for metabolic and inflammatory diseases.", "age_days": 18.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "negative", "story_key": "aaceb12320892b5581124b9f0df80a4067b72d62fa0e09ea0c8543b07334ea64", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/belite-bio-nasdaqblte-stock-rating-lowered-by-zacks-research-2026-08-20", "source_name": "MarketBeat", "published_at": "2026-08-20T11:40:42", "source_names": ["MarketBeat"], "target_scope": "Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Zacks Research Zacks Research has downgraded Belite Bio (NASDAQ:BLTE) from a \"strong buy\" to a \"hold\" rating, despite a broader analyst consensus of \"moderate buy\" with a $205.80 price target.", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 1.5, "sentiment_pct": 43, "evidence_basis": "archived_article", "evidence_share": 0.3, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.001549, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.51, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 29, "published_display": "20 Aug 2026 11:40", "direction_included": true, "sentiment_conflict": 0.439, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.3", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.017}, {"url": "https://www.reveliolabs.com/companies/belite-bio/employees", "tier": "direct", "title": "Belite Bio Number of Employees 2026 | Employee Count & Headcount Data", "topics": ["Earnings", "Life Sciences"], "summary": "Belite Bio, Inc. (NASDAQ: BLTE) had approximately 50 employees worldwide as of March 2026, representing a 232.6% growth from 2023. The company is actively hiring, with 1 active job posting in 2026, and its workforce is primarily concentrated in North America. The average salary is $151,597, with significant regional variations.", "age_days": 19.2, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "8106829aabc2eaca51e7f7cb89472c299001c754e1e9a0fbc5c66d9f72636d34", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.reveliolabs.com/companies/belite-bio/employees", "source_name": "Revelio Labs", "published_at": "2026-08-19T09:10:20", "source_names": ["Revelio Labs"], "target_scope": "Belite Bio Number of Employees 2026 | Employee Count & Headcount Data Belite Bio, Inc. (NASDAQ: BLTE) had approximately 50 employees worldwide as of March 2026, representing a 232.6% growth from 2023.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 7.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.006719, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "19 Aug 2026 09:10", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.3959}, {"url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQZmZHb3dJNlZGTW1aM0dVNVpXZ3F0cXpjYTh0bG9HVmhrMzlJOVRIV0ltOXdrS1F5Z3MzdEx6YTBkVDVNdk41cURNTHhBUXBvWTA1aEFQUkRSeFhaNjRWbzdSQTVnWnZJTGFMbzBFM2dCTHVPTkZTUkRQdUJsWjBMQ3RvZ0E0V0JsT3QzSTlabnZHMm0tdFFvbW1lMnc1WmFjbnAzZ1ZCVGVCSUJLWHoxMXcybVhUU1VKOG1XOV9NVXVrcWp4Y1RpeHJNbkYwc0lZbkxTcGItVW9tY0pXbjBPS3RGNmtnVTV3VnBWVXZDZTlWUUhnZl9lQU1nOUhfOXlf?oc=5", "tier": "direct", "title": "Belite (BLTE) Earnings Brief: EPS Falls Short of Its Estimate on the Day; Market Read: Shares Finish 0.39% Down in the Current Update - Revenue Report", "topics": [], "summary": "", "age_days": 20.3, "is_stale": false, "provider": "google_news", "providers": ["archive", "google_news"], "sentiment": "negative", "story_key": "bbbfcfd60eac6ee6c6492f4b80c70ea38caccaf8b322e00c1740369de5cf8e3f", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQZmZHb3dJNlZGTW1aM0dVNVpXZ3F0cXpjYTh0bG9HVmhrMzlJOVRIV0ltOXdrS1F5Z3MzdEx6YTBkVDVNdk41cURNTHhBUXBvWTA1aEFQUkRSeFhaNjRWbzdSQTVnWnZJTGFMbzBFM2dCTHVPTkZTUkRQdUJsWjBMQ3RvZ0E0V0JsT3QzSTlabnZHMm0tdFFvbW1lMnc1WmFjbnAzZ1ZCVGVCSUJLWHoxMXcybVhUU1VKOG1XOV9NVXVrcWp4Y1RpeHJNbkYwc0lZbkxTcGItVW9tY0pXbjBPS3RGNmtnVTV3VnBWVXZDZTlWUUhnZl9lQU1nOUhfOXlf?oc=5", "source_name": "dars.gov.et", "published_at": "2026-08-18T07:00:00+00:00", "source_names": ["dars.gov.et", "vinanet.vn"], "target_scope": "Belite (BLTE) Earnings Brief: EPS Falls Short of Its Estimate on the Day", "tone_signals": ["Missed expectations"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 6.0, "sentiment_pct": 25, "evidence_basis": "headline_only", "evidence_share": 2.1, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.012862, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.59, "provider_symbols": ["BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 52, "published_display": "18 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.1", "target_provider_symbol": "BLTE.ARCHIVE", "provider_directional_mass": null}, {"url": "https://m.investing.com/news/insider-trading-news/belite-bio-ceo-lin-yuhsin-sells-company-stock-over-65000-93CH-4860272?ampMode=1", "tier": "direct", "title": "Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio CEO Lin Yu-Hsin sold 365 American depositary shares worth over $65,000 on August 12, 2026, as part of a Rule 10b5-1 trading plan. Despite the stock's remarkable 141% return over the past year, shares have recently declined to $166.28 from the transaction price of around $180. Additionally, Belite Bio reported a smaller-than-expected loss for Q2 2026, with an adjusted EPS of -$0.54, exceeding analysts' estimates.", "age_days": 23.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "negative", "story_key": "749aedb71705f6497cc42169ae26df5051d305259354e1c9bd7066dd61a398b5", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://m.investing.com/news/insider-trading-news/belite-bio-ceo-lin-yuhsin-sells-company-stock-over-65000-93CH-4860272?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-14T19:41:05", "source_names": ["Investing.com"], "target_scope": "Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000 Belite Bio CEO Lin Yu-Hsin sold 365 American depositary shares worth over $65,000 on August 12, 2026, as part of a Rule 10b5-1 trading plan. Additionally, Belite Bio reported a smaller-than-expected loss for Q2 2026, with an adjusted EPS of -$0.54, exceeding analysts' estimates.", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.7, "sentiment_pct": 38, "evidence_basis": "archived_article", "evidence_share": 1.8, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.010966, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.655, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 39, "published_display": "14 Aug 2026 19:41", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.8", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.2102}, {"url": "https://www.investing.com/news/analyst-ratings/benchmark-reiterates-belite-bio-stock-rating-on-fda-priority-review-93CH-4860741", "tier": "direct", "title": "Benchmark reiterates Belite Bio stock rating on FDA priority review", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Benchmark has reiterated a Buy rating and a $217.00 price target for Belite Bio (NASDAQ:BLTE) after the FDA granted Priority Review to the company's New Drug Application for Tinlarebant, targeting a PDUFA date of February 12, 2027. Belite Bio plans significant R&D and marketing investments for Tinlarebant's commercial launch in Q1 2027 and is well-capitalized with $280 million in cash and $500 million in investments. This follows a smaller-than-expected Q2 2026 loss and a raised price target from Mizuho.", "age_days": 23.8, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "5037ee004c6d31ba1b8253dd7e39e2415907562a7c307c1bddb223a53c3717fe", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.investing.com/news/analyst-ratings/benchmark-reiterates-belite-bio-stock-rating-on-fda-priority-review-93CH-4860741", "source_name": "Investing.com", "published_at": "2026-08-14T19:11:36", "source_names": ["Investing.com"], "target_scope": "Benchmark reiterates Belite Bio stock rating on FDA priority review Benchmark has reiterated a Buy rating and a $217.00 price target for Belite Bio (NASDAQ:BLTE) after the FDA granted Priority Review to the company's New Drug Application for Tinlarebant, targeting a PDUFA date of February 12, 2027. Belite Bio plans significant R&D and marketing investments for Tinlarebant's commercial launch in Q1 2027 and is well-capitalized with $280 million in cash and $500 million in investments.", "tone_signals": ["Analyst upgrade", "Buy Rating", "Contract or approval won"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.4, "sentiment_pct": 64, "evidence_basis": "archived_article", "evidence_share": 0.2, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.001126, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.738, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 38, "published_display": "14 Aug 2026 19:11", "direction_included": true, "sentiment_conflict": 0.117, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.2", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.4288}, {"url": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-blte-stock-looks-151152548.html", "tier": "direct", "title": "Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run", "topics": ["Clinical Trials", "Earnings", "Fda Approval", "Financial Markets", "Life Sciences", "Overvaluation"], "summary": "Belite Bio (BLTE) stock has experienced a significant 431.2% return over the past three years. Despite this impressive performance and regulatory progress for its drug tinlarebant, valuation metrics suggest the stock may be fully priced, trading at a P/B ratio significantly above the industry average. The article suggests that future movements will depend on whether current pricing already accounts for the potential cash generation from its clinical and regulatory milestones.", "age_days": 23.9, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "ba231c6163fe8855e83edc4e55ac99b2d1c78480ceeb9a9ffc67dfa874a5fcb9", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-blte-stock-looks-151152548.html", "source_name": "Simply Wall St.", "published_at": "2026-08-14T15:11:52+00:00", "source_names": ["Simply Wall St."], "target_scope": "Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run Belite Bio (BLTE) stock has experienced a significant 431.2% return over the past three years.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.003479, "influence_label": "None", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "archive", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BLTE", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "14 Aug 2026 15:11", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.sahmcapital.com/news/content/belite-bio-blte-could-be-21-below-fair-value-as-fda-priority-review-lands-2026-08-15", "tier": "direct", "title": "Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands", "topics": ["Biotech", "Earnings", "Fda Approval", "Financial Markets", "Intrinsic Value", "Life Sciences"], "summary": "Belite Bio (BLTE) is drawing attention after the FDA granted Priority Review to its New Drug Application for tinlarebant, a Stargardt Disease Type 1 treatment. Despite a recent stock pullback following a quarterly loss, the company is considered undervalued by 21.4% according to analyst targets and its fair value estimate of $211.50, driven by its strong cash position and planned R&D and commercialization investments. However, its valuation also carries uncertainties regarding regulatory decisions and expansion data.", "age_days": 24.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "c8574272159389c2eb50e8f5f59b9b910135866f8a5cead9eaacd195b89a01a0", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.sahmcapital.com/news/content/belite-bio-blte-could-be-21-below-fair-value-as-fda-priority-review-lands-2026-08-15", "source_name": "Sahm", "published_at": "2026-08-14T12:42:17", "source_names": ["Sahm"], "target_scope": "Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands Belite Bio (BLTE) is drawing attention after the FDA granted Priority Review to its New Drug Application for tinlarebant, a Stargardt Disease Type 1 treatment.", "tone_signals": ["Contract or approval won", "Positive valuation view"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.6, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 1.1, "score_included": true, "duplicate_count": 4, "durable_archive": false, "evidence_weight": 0.00648, "influence_label": "Low", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.625, "provider_symbols": ["BLTE", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 33, "published_display": "14 Aug 2026 12:42", "direction_included": true, "sentiment_conflict": 0.235, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.1", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.3298}, {"url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNMG94TkQ0S1pJVjBzRnlKd1V3ZkNMcTVHMkR0YXMyS3lDYzlVR1VfakdiNllBMmJHcXctUWJ1V2NoZXhNQmRhTm4zcVNoWWpfajZGZ0FUY3pZTGtRbVB0RHZCamlIT1hoNTcwOVVYcExFUWZpazFEcVUtTWVuNFBmSmRDZ2lUMnZYOE5LMHZnZUZWTUlvSXJrY2I3MDZ6cnRXcW53cnFoZ0dUejBTd1l1Skt0Tk04M3h3b3MxdmJYeUkxeUNpS2c?oc=5", "tier": "direct", "title": "Mizuho raises Belite Bio stock price target to $220 on NDA progress", "topics": [], "summary": "", "age_days": 24.1, "is_stale": false, "provider": "google_news", "providers": ["archive", "google_news"], "sentiment": "positive", "story_key": "aece32cbceb89690dda7a95a948f5c558c8baa9211a9ec2cdde2a081b4c11af6", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNMG94TkQ0S1pJVjBzRnlKd1V3ZkNMcTVHMkR0YXMyS3lDYzlVR1VfakdiNllBMmJHcXctUWJ1V2NoZXhNQmRhTm4zcVNoWWpfajZGZ0FUY3pZTGtRbVB0RHZCamlIT1hoNTcwOVVYcExFUWZpazFEcVUtTWVuNFBmSmRDZ2lUMnZYOE5LMHZnZUZWTUlvSXJrY2I3MDZ6cnRXcW53cnFoZ0dUejBTd1l1Skt0Tk04M3h3b3MxdmJYeUkxeUNpS2c?oc=5", "source_name": "Investing.com India", "published_at": "2026-08-14T11:30:09+00:00", "source_names": ["Investing.com", "Investing.com India"], "target_scope": "Mizuho raises Belite Bio stock price target to $220 on NDA progress", "tone_signals": ["Analyst upgrade"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.4, "sentiment_pct": 69, "evidence_basis": "headline_only", "evidence_share": 0.1, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000777, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.57, "provider_symbols": ["BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 42, "published_display": "14 Aug 2026 11:30", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.1", "target_provider_symbol": "BLTE.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.marketscreener.com/news/mizuho-adjusts-price-target-on-belite-bio-to-220-from-215-maintains-outperform-rating-ce7859dede8ef526", "tier": "direct", "title": "Mizuho Adjusts Price Target on Belite Bio to $220 From $215, Maintains Outperform Rating", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Mizuho has increased its price target for Belite Bio (NASDAQ:BLTE) to $220 from $215, while reaffirming an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm. The biopharmaceutical company is focused on developing novel therapeutics for retinal degenerative eye diseases and metabolic conditions.", "age_days": 24.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "b1c055b6c844b05b33b0e6d4b13dd3f8741726edc2c39a8d0944905dfeccd733", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/mizuho-adjusts-price-target-on-belite-bio-to-220-from-215-maintains-outperform-rating-ce7859dede8ef526", "source_name": "www.marketscreener.com", "published_at": "2026-08-14T11:12:55", "source_names": ["www.marketscreener.com"], "target_scope": "Mizuho Adjusts Price Target on Belite Bio to $220 From $215, Maintains Outperform Rating Mizuho has increased its price target for Belite Bio (NASDAQ:BLTE) to $220 from $215, while reaffirming an Outperform rating on the stock.", "tone_signals": ["Analyst upgrade"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.4, "sentiment_pct": 67, "evidence_basis": "archived_article", "evidence_share": 0.1, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000676, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 93, "model_confidence": 0.608, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 40, "published_display": "14 Aug 2026 11:12", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.1", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.2873}, {"url": "https://www.marketbeat.com/instant-alerts/yu-hsin-lin-sells-365-shares-of-belite-bio-nasdaqblte-stock-2026-08-14", "tier": "direct", "title": "Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio CEO Yu-Hsin Lin sold 365 shares of the company's stock for a total of $65,827.75, reducing his ownership by 0.21%. Despite the sale, analyst sentiment remains largely positive with a \"Moderate Buy\" consensus and a target price of $204.40, especially following the FDA's priority review of tinlarebant. However, Belite Bio remains a clinical-stage company reporting ongoing losses, making its valuation dependent on regulatory decisions and clinical success.", "age_days": 24.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "negative", "story_key": "a3203687840d3483210ab23d834c8d27917af5eda5f713d4e87454afd980343d", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/yu-hsin-lin-sells-365-shares-of-belite-bio-nasdaqblte-stock-2026-08-14", "source_name": "MarketBeat", "published_at": "2026-08-14T11:12:55", "source_names": ["MarketBeat"], "target_scope": "Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock Belite Bio CEO Yu-Hsin Lin sold 365 shares of the company's stock for a total of $65,827.75, reducing his ownership by 0.21%. However, Belite Bio remains a clinical-stage company reporting ongoing losses, making its valuation dependent on regulatory decisions and clinical success.", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.5, "sentiment_pct": 40, "evidence_basis": "archived_article", "evidence_share": 1.2, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.007045, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.637, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 36, "published_display": "14 Aug 2026 11:12", "direction_included": true, "sentiment_conflict": 0.2, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.2", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.2857}, {"url": "https://finance.yahoo.com/healthcare/articles/belite-bio-inc-blte-q2-070022030.html", "tier": "direct", "title": "Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...", "topics": ["Clinical Trials", "Earnings", "Fda Approval", "Pharma", "Rare Diseases"], "summary": "This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant with Priority Review, establishing a PDUFA date of February 12, 2027. New secondary endpoint data from the Phase 3 DRAGON study presented at ASRS showed that Tinlarabant halted or slightly decreased QAF values (by ~2%) at month 25, compared to a ~20% increase in the placebo group. The company is initiating ", "age_days": 24.3, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "positive", "story_key": "0dbf9a8a197e7b3ff02f5a94319d977b3012597d2bd8092fd77ab218c31eab7e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/belite-bio-inc-blte-q2-070022030.html", "source_name": "GuruFocus.com", "published_at": "2026-08-14T07:00:22+00:00", "source_names": ["GuruFocus.com"], "target_scope": "Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant with Priority Review, establishing a PDUFA date of February 12, 2027.", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.5, "sentiment_pct": 59, "evidence_basis": "headline_only", "evidence_share": 0.8, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.005036, "influence_label": "Low", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.481, "provider_symbols": ["BLTE", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 33, "published_display": "14 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.8", "target_provider_symbol": "BLTE", "provider_directional_mass": null}, {"url": "https://m.investing.com/news/transcripts/earnings-call-transcript-belite-bio-beats-q2-2026-eps-view-as-stock-slips-93CH-4859329?ampMode=1", "tier": "direct", "title": "Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips", "topics": ["Clinical Trials", "Earnings", "Fda Approval", "Life Sciences", "Pharma", "Rare Diseases"], "summary": "Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A expenses in preparation for commercialization, Belite Bio maintains a strong cash balance of $780 million to fund future operations and development.", "age_days": 24.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage", "archive", "google_news"], "sentiment": "positive", "story_key": "ef4bf29360d12163047e298c4ca8a7275b5d473b0fe1e835339fe3ed0dd3b4c7", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://m.investing.com/news/transcripts/earnings-call-transcript-belite-bio-beats-q2-2026-eps-view-as-stock-slips-93CH-4859329?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-13T21:40:51", "source_names": ["Investing.com"], "target_scope": "Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. Despite rising R&D and SG&A expenses in preparation for commercialization, Belite Bio maintains a strong cash balance of $780 million to fund future operations and development.", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.3, "sentiment_pct": 75, "evidence_basis": "archived_article", "evidence_share": 2.2, "score_included": true, "duplicate_count": 5, "durable_archive": false, "evidence_weight": 0.013396, "influence_label": "Medium", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.708, "provider_symbols": ["BLTE", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 52, "published_display": "13 Aug 2026 21:40", "direction_included": true, "sentiment_conflict": 0.251, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.2", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.3908}, {"url": "https://www.sahmcapital.com/news/content/belite-bio-blte-is-up-129-after-fda-priority-review-for-tinlarebant-in-stargardt-disease-2026-08-13", "tier": "direct", "title": "Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease", "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "Earnings", "FDA-APPROVAL"], "summary": "Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. The PDUFA target action date is set for February 12, 2027, and if approved, tinlarebant would be the first FDA-approved treatment for this rare retinal disease. This development significantly sharpens Belite Bio's investment narrative, moving it from clinical execution to regulatory resolution, with potential revenue projections of $563.2 million and earnings of $318.3 million by 2029.", "age_days": 24.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "2141d80b890142b60f7cba9ab2b6f078139de8ff33c9f6c2143f81651dcd0a73", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.sahmcapital.com/news/content/belite-bio-blte-is-up-129-after-fda-priority-review-for-tinlarebant-in-stargardt-disease-2026-08-13", "source_name": "Sahm", "published_at": "2026-08-13T19:41:05", "source_names": ["Sahm"], "target_scope": "Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. This development significantly sharpens Belite Bio's investment narrative, moving it from clinical execution to regulatory resolution, with potential revenue projections of $563.2 million and earnings of $318.3 million by 2029.", "tone_signals": ["Contract or approval won", "Institutional or insider buying"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.2, "sentiment_pct": 58, "evidence_basis": "archived_article", "evidence_share": 0.8, "score_included": true, "duplicate_count": 4, "durable_archive": false, "evidence_weight": 0.004621, "influence_label": "Low", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.629, "provider_symbols": ["AMD.US", "BLTE", "BLTE.ARCHIVE", "BLTE.US", "CI"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 30, "published_display": "13 Aug 2026 19:41", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0.8", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.4692}, {"url": "https://www.marketbeat.com/instant-alerts/belite-bio-nasdaqblte-stock-price-down-72-should-you-sell-2026-08-13", "tier": "direct", "title": "Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Should You Sell?", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio (NASDAQ:BLTE) stock declined 7.2% to $166.11 on Thursday, with trading volume below its average. Despite the drop, analysts have a \"Moderate Buy\" consensus rating with an average price target of $204.40. The company, a clinical-stage biotechnology firm, reported a narrower-than-expected quarterly loss of $0.54 per share.", "age_days": 24.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "987fb0ab8feb8b81c2758a1171c97fb64dee89835f8d1969c78c92615f494f34", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/belite-bio-nasdaqblte-stock-price-down-72-should-you-sell-2026-08-13", "source_name": "MarketBeat", "published_at": "2026-08-13T19:40:51", "source_names": ["MarketBeat"], "target_scope": "Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Should You Sell? Belite Bio (NASDAQ:BLTE) stock declined 7.2% to $166.11 on Thursday, with trading volume below its average.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.003504, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.451, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 19:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.2271}, {"url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOd3FyZE8xYVdZS2hjN253cTd4cXRJTjNpWm1Zbm5mQWVIbGE4c3c2YjM5eTRscnA1TmlVX0VjS1o2NGdzVU42bndhY2RCSm41d1Z5Yk43R0I2VlR3TTFuRjd1c3U2Wkh6NEl6US1FVGJPbEgtQlhMS0gzS2t4amlieFhFdnU2QTU3dWV6WkVXZzN2aDRPZzNHaEg4MDVZX1VCYWxYbHFhR3hkX2xtbjN5T2xJME9rNEVpUTVnQzdaYWhSS01HQUEwZUo2UTlMcU1M?oc=5", "tier": "direct", "title": "Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS", "topics": [], "summary": "", "age_days": 24.8, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "6f242c9709edef3d9e26fcd0b0d224564bc93b8b6a175a3fa9470ac60078ed58", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOd3FyZE8xYVdZS2hjN253cTd4cXRJTjNpWm1Zbm5mQWVIbGE4c3c2YjM5eTRscnA1TmlVX0VjS1o2NGdzVU42bndhY2RCSm41d1Z5Yk43R0I2VlR3TTFuRjd1c3U2Wkh6NEl6US1FVGJPbEgtQlhMS0gzS2t4amlieFhFdnU2QTU3dWV6WkVXZzN2aDRPZzNHaEg4MDVZX1VCYWxYbHFhR3hkX2xtbjN5T2xJME9rNEVpUTVnQzdaYWhSS01HQUEwZUo2UTlMcU1M?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-13T18:34:44+00:00", "source_names": ["MarketBeat"], "target_scope": "Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.2, "sentiment_pct": 75, "evidence_basis": "headline_only", "evidence_share": 1.1, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.006876, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 69, "model_confidence": 0.59, "provider_symbols": ["BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 51, "published_display": "13 Aug 2026 18:34", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.1", "target_provider_symbol": "BLTE.ARCHIVE", "provider_directional_mass": null}, {"url": "https://glance.eyesoneyecare.com/stories/2026-08-12/fda-accepts-belite-s-tinlarebant-nda-for-stargardt", "tier": "direct", "title": "FDA accepts Belite's tinlarebant NDA for Stargardt", "topics": ["Life Sciences"], "summary": "Belite Bio, Inc. has received FDA acceptance for its new drug application (NDA) for tinlarebant, an investigational therapy for Stargardt disease type 1 (STGD1). The FDA has granted tinlarebant a priority review, setting the PDUFA target action date for February 12, 2027. If approved, tinlarebant would be the first-ever treatment for STGD1.", "age_days": 25.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "714c188ae44c846112902c71e4bcbe358d0e50993d15f68aec869fcb2c389b6a", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://glance.eyesoneyecare.com/stories/2026-08-12/fda-accepts-belite-s-tinlarebant-nda-for-stargardt", "source_name": "Glance by Eyes On Eyecare", "published_at": "2026-08-13T12:42:17", "source_names": ["Glance by Eyes On Eyecare"], "target_scope": "FDA accepts Belite's tinlarebant NDA for Stargardt Belite Bio, Inc.", "tone_signals": ["Contract or approval won"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 1.7e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.533, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 12:42", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.8348}, {"url": "https://www.nasdaq.com/articles/belite-bio-q2-net-loss-widens-fda-sets-pdufa-date-tinlarebant-february-2027", "tier": "direct", "title": "Belite Bio Q2 Net Loss Widens; FDA Sets PDUFA Date For Tinlarebant In February 2027", "topics": ["Biotech", "Clinical Trials", "Earnings", "Fda Approval", "Financial Results"], "summary": "(RTTNews) - Belite Bio, Inc (BLTE), a clinical-stage drug development company, announced its financial results for the second quarter, reflecting a wider net loss. The company also provided an update on its New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1), an inherited macular dystrophy condition. Company Profile Belite Bio focuses on degenerative retinal diseases such as Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio's lead can", "age_days": 25.2, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "negative", "story_key": "afbf5d008ecccdccac40554e7eabb7b3bdce63203f7c11b48842a8b2ca9fd76e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.nasdaq.com/articles/belite-bio-q2-net-loss-widens-fda-sets-pdufa-date-tinlarebant-february-2027", "source_name": "nasdaq.com", "published_at": "2026-08-13T09:42:05+00:00", "source_names": ["nasdaq.com"], "target_scope": "Belite Bio Q2 Net Loss Widens (RTTNews) - Belite Bio, Inc (BLTE), a clinical-stage drug development company, announced its financial results for the second quarter, reflecting a wider net loss. Company Profile Belite Bio focuses on degenerative retinal diseases such as Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio's lead can", "tone_signals": ["Loss widened"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 3.1, "sentiment_pct": 30, "evidence_basis": "archived_article", "evidence_share": 0.7, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.0045, "influence_label": "Medium", "provider_symbol": "BLTE.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.586, "provider_symbols": ["AMD.US", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 42, "published_display": "13 Aug 2026 09:42", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0.7", "target_provider_symbol": "BLTE.US", "provider_directional_mass": 0.036}, {"url": "https://www.stocktitan.net/sec-filings/BLTE/6-k-belite-bio-inc-current-report-foreign-issuer-f8d7b1bcd4d1.html", "tier": "direct", "title": "Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss", "topics": ["Earnings", "Life Sciences"], "summary": "Belite Bio announced that the FDA accepted its New Drug Application for tinlarebant with Priority Review for treating Stargardt disease type 1, setting a PDUFA target action date of February 12, 2027. Despite this regulatory progress, the company reported a wider net loss of $28.4 million for Q2 2026, up from $16.3 million a year prior, due to increased R&D and SG&A expenses as it prepares for tinlarebant's potential launch. Belite Bio maintains strong liquidity with $279.9 million in cash and equivalents and $500.1 million in U.S. treasury investments.", "age_days": 25.2, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "negative", "story_key": "a4e1e596f619ea8dca765dd2028fd60087ee563db2e4ddecd42b19fcea2d8b6a", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/BLTE/6-k-belite-bio-inc-current-report-foreign-issuer-f8d7b1bcd4d1.html", "source_name": "Stock Titan", "published_at": "2026-08-13T09:40:51", "source_names": ["Stock Titan"], "target_scope": "Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss Belite Bio announced that the FDA accepted its New Drug Application for tinlarebant with Priority Review for treating Stargardt disease type 1, setting a PDUFA target action date of February 12, 2027. Belite Bio maintains strong liquidity with $279.9 million in cash and equivalents and $500.1 million in U.S.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 8.3, "sentiment_pct": 43, "evidence_basis": "archived_article", "evidence_share": 2.1, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.012507, "influence_label": "Low", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.455, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 32, "published_display": "13 Aug 2026 09:40", "direction_included": true, "sentiment_conflict": 0.244, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.1", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.1312}, {"url": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-q2-non-gaap-073955534.html", "tier": "direct", "title": "Belite Bio Q2 Non-GAAP Net Loss Widens", "topics": [], "summary": "", "age_days": 25.2, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "negative", "story_key": "db12089277040a9e639087f7a11b470651379abcd1bfd722cbc31f9e34fd076e", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/belite-bio-q2-non-gaap-073955534.html", "source_name": "MT Newswires", "published_at": "2026-08-13T07:39:55+00:00", "source_names": ["MT Newswires"], "target_scope": "Belite Bio Q2 Non-GAAP Net Loss Widens", "tone_signals": ["Loss widened"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 32, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 1.9e-05, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "yfinance", "event_confidence": 35, "model_confidence": 0.566, "provider_symbols": ["BLTE", "BLTE.ARCHIVE", "FDS"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 41, "published_display": "13 Aug 2026 07:39", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1", "target_provider_symbol": "BLTE.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOYzE2eXItYXV3Njh6dmlCaGU4X0VXLXdoaWdMdzVIUjVoQTVlb0FsZEVOc1d3YnU4bXlyUHFpb1ZzcHAwMkN5UlpET2JEUG9Ed19FNWFZYnBPMDlpcTg3QnZIcXFGTkxRNy14dGxhWExVbllmVDhFSmhlSE9sYXlhdzZla1R4RVd3SEFyZm9BcG45VmttdWxxeE83T1E1d2FLOE1aVVBtcVBfSHBVbXJBQVFWR0JyTGdH?oc=5", "tier": "direct", "title": "Belite Bio will give a second-quarter business update Aug. 13", "topics": [], "summary": "", "age_days": 25.3, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "8ef771072e444f4edfe6725251f046eb8765120853bf7370ad3a7aaaa33bf51a", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOYzE2eXItYXV3Njh6dmlCaGU4X0VXLXdoaWdMdzVIUjVoQTVlb0FsZEVOc1d3YnU4bXlyUHFpb1ZzcHAwMkN5UlpET2JEUG9Ed19FNWFZYnBPMDlpcTg3QnZIcXFGTkxRNy14dGxhWExVbllmVDhFSmhlSE9sYXlhdzZla1R4RVd3SEFyZm9BcG45VmttdWxxeE83T1E1d2FLOE1aVVBtcVBfSHBVbXJBQVFWR0JyTGdH?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-13T07:00:00+00:00", "source_names": ["Stock Titan"], "target_scope": "Belite Bio will give a second-quarter business update Aug.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 8e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/belite-bio-reports-unaudited-second-014500110.html", "tier": "direct", "title": "Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update", "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "Earnings", "FDA-APPROVAL"], "summary": "Belite Bio announced its second-quarter 2026 financial results, highlighting significant progress in the development of tinlarebant for Stargardt disease type 1 (STGD1), including the FDA's acceptance of its New Drug Application with Priority Review. The company reported increased R&D and SG&A expenses due to milestone payments, manufacturing, and team expansion, resulting in a net loss of $28.4 million for the quarter. Belite Bio also provided updates on its DRAGON II and PHOENIX trials and ongoing commercialization preparations.", "age_days": 25.5, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "7e4e36d0c2a5863abe67e312c64f08ca68bfcc12f6b0656789ce2e0e4b7d1d3d", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "press_release", "source_link": "https://finance.yahoo.com/healthcare/articles/belite-bio-reports-unaudited-second-014500110.html", "source_name": "GlobeNewswire", "published_at": "2026-08-13T01:45:00+00:00", "source_names": ["GlobeNewswire"], "target_scope": "Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update Belite Bio announced its second-quarter 2026 financial results, highlighting significant progress in the development of tinlarebant for Stargardt disease type 1 (STGD1), including the FDA's acceptance of its New Drug Application with Priority Review. Belite Bio also provided updates on its DRAGON II and PHOENIX trials and ongoing commercialization preparations.", "tone_signals": ["Negative financial language"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 2.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.002739, "influence_label": "None", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "archive", "event_confidence": 69, "model_confidence": 0.45, "provider_symbols": ["AMD.US", "BLTE", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "13 Aug 2026 01:45", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/blte-stock-rises-fda-grants-125400613.html", "tier": "direct", "title": "BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA", "topics": ["Biotech", "Clinical Trials", "Earnings", "Earnings Per Share", "Fda Approval", "Growth Rate"], "summary": "Belite Bio BLTE announced that the FDA has accepted the new drug application (NDA) seeking approval for its lead candidate, tinlarebant, for the treatment of patients with Stargardt Disease type I (STGD1). With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on Feb. 12, 2027. Shares rose around 6.2% on Tuesday following the announcement. A priority review designation means the FDA's goal is to take action on an application within six months compared with 10 months under standard review. If approved, tinlarebant would become the first FDA-approved ", "age_days": 26.0, "is_stale": false, "provider": "yfinance", "providers": ["archive", "yfinance"], "sentiment": "positive", "story_key": "10e930e8eedf8b2089615e04e8572b79c89e65f0da0ca53446e7d7e3add493a6", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/blte-stock-rises-fda-grants-125400613.html", "source_name": "Zacks", "published_at": "2026-08-12T12:54:00+00:00", "source_names": ["Zacks"], "target_scope": "BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA Belite Bio BLTE announced that the FDA has accepted the new drug application (NDA) seeking approval for its lead candidate, tinlarebant, for the treatment of patients with Stargardt Disease type I (STGD1).", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 2.7, "sentiment_pct": 72, "evidence_basis": "archived_article", "evidence_share": 1.1, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.006396, "influence_label": "Medium", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.667, "provider_symbols": ["ALT", "ALT.US", "AMRX", "BLTE", "BLTE.ARCHIVE", "LQDA"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 45, "published_display": "12 Aug 2026 12:54", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "1.1", "target_provider_symbol": "BLTE", "provider_directional_mass": null}, {"url": "https://m.investing.com/news/analyst-ratings/belite-bio-stock-price-target-raised-to-214-by-hc-wainwright-on-fda-review-93CH-4854826?ampMode=1", "tier": "direct", "title": "Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "H.C. Wainwright has increased its price target for Belite Bio (NASDAQ:BLTE) to $214 from $200, maintaining a Buy rating, after the FDA granted Priority Review to the New Drug Application for tinlarebant, a treatment for Stargardt disease type 1. The drug, which has shown significant reduction in retinal lesion growth in trials, has also received Breakthrough Therapy and Orphan Drug designations. The FDA is set to make a decision by February 12, 2027, and Belite Bio is expected to report Q2 2026 results soon.", "age_days": 26.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "4714330b354cbeb5f27fc04014833c09816b5e9bf18f588a879f95678d8e0d3e", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://m.investing.com/news/analyst-ratings/belite-bio-stock-price-target-raised-to-214-by-hc-wainwright-on-fda-review-93CH-4854826?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-12T12:11:21", "source_names": ["Investing.com"], "target_scope": "Belite Bio stock price target raised to $214 by H.C. Wainwright has increased its price target for Belite Bio (NASDAQ:BLTE) to $214 from $200, maintaining a Buy rating, after the FDA granted Priority Review to the New Drug Application for tinlarebant, a treatment for Stargardt disease type 1. The FDA is set to make a decision by February 12, 2027, and Belite Bio is expected to report Q2 2026 results soon.", "tone_signals": ["Analyst upgrade", "Buy Rating", "Contract or approval won"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.2, "sentiment_pct": 80, "evidence_basis": "archived_article", "evidence_share": 0.2, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.000965, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 85, "model_confidence": 0.792, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 55, "published_display": "12 Aug 2026 12:11", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.2", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.8305}, {"url": "https://seekingalpha.com/news/4631365-belite-bio-lead-asset-granted-fda-priority-review", "tier": "direct", "title": "Belite Bio lead asset granted FDA priority review (BLTE:NASDAQ)", "topics": ["Financial Markets", "Life Sciences"], "summary": "The FDA has accepted Belite Bio's marketing application for its lead asset, tinlarebant, granting it priority review. This therapy targets an eye disease, and the FDA has set a target action date of February 12, 2027.", "age_days": 26.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "dae937b900cc648fdf972dbb7ad96098c657dad1d19332471b3ab6d20df58dff", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://seekingalpha.com/news/4631365-belite-bio-lead-asset-granted-fda-priority-review", "source_name": "Seeking Alpha", "published_at": "2026-08-12T11:11:21", "source_names": ["Seeking Alpha"], "target_scope": "Belite Bio lead asset granted FDA priority review (BLTE:NASDAQ) The FDA has accepted Belite Bio's marketing application for its lead asset, tinlarebant, granting it priority review.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 9e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 11:11", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.8057}, {"url": "https://finance.yahoo.com/healthcare/articles/belite-bio-announces-u-food-200100791.html", "tier": "direct", "title": "Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1", "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Growth Rate", "Life Sciences", "Pharma"], "summary": "Belite Bio announced that the FDA has accepted and granted Priority Review for its New Drug Application (NDA) for tinlarebant, aimed at treating Stargardt Disease Type 1 (STGD1). The FDA set a PDUFA date of February 12, 2027, and if approved, tinlarebant would be the first-ever treatment for this rare, inherited retinal disease. The NDA is supported by positive results from the Phase 3 DRAGON trial, showing a significant reduction in the growth rate of atrophic retinal lesions.", "age_days": 26.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "1f59396929a89d09f5c36d05abb0a14a7b0d6a1ca5333d882ef38c01ce4764b4", "event_type": "regulatory", "tier_label": "Direct company coverage", "event_label": "Regulatory and legal", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/belite-bio-announces-u-food-200100791.html", "source_name": "Market source", "published_at": "2026-08-11T19:45:16", "source_names": ["Market source"], "target_scope": "Belite Bio Announces U.S. Belite Bio announced that the FDA has accepted and granted Priority Review for its New Drug Application (NDA) for tinlarebant, aimed at treating Stargardt Disease Type 1 (STGD1).", "tone_signals": ["Contract or approval won"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 7.1, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 1.5, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.009297, "influence_label": "Low", "provider_symbol": "BLTE.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.553, "provider_symbols": ["AMD.US", "BLTE", "BLTE.ARCHIVE", "BLTE.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 30, "published_display": "11 Aug 2026 19:45", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "1.5", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.8041}, {"url": "https://www.marketbeat.com/instant-alerts/belite-bio-inc-sponsored-adr-nasdaqblte-receives-average-rating-of-moderate-buy-from-brokerages-2026-08-09", "tier": "direct", "title": "Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of \"Moderate Buy\" from Brokerages", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) has received a consensus \"Moderate Buy\" rating from brokerages, with an average 12-month price target of $203.00. The company recently reported a quarterly loss of $0.34 per share, beating analyst estimates. Despite an insider selling 10,000 shares, institutional ownership remains limited.", "age_days": 28.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "51d6b1d04bb3305b595020d1d8af9d0d19f3334e97d45e3b1458b96403714ad7", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/belite-bio-inc-sponsored-adr-nasdaqblte-receives-average-rating-of-moderate-buy-from-brokerages-2026-08-09", "source_name": "MarketBeat", "published_at": "2026-08-09T23:11:21", "source_names": ["MarketBeat"], "target_scope": "Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of \"Moderate Buy\" from Brokerages Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) has received a consensus \"Moderate Buy\" rating from brokerages, with an average 12-month price target of $203.00.", "tone_signals": ["Negative financial language"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 8.9e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.45, "provider_symbols": ["AXON", "BLTE", "BLTE.ARCHIVE", "UBER"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "09 Aug 2026 23:11", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.3302}, {"url": "https://news.stocktradersdaily.com/news_release/1/How_Belite_Bio_Inc_BLTE_Affects_Rotational_Strategy_Timing_080926065202_1786272722.html", "tier": "direct", "title": "How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing", "topics": ["Financial Markets", "Life Sciences"], "summary": "This article analyzes Belite Bio Inc (BLTE) and its impact on rotational trading strategies. It highlights strong sentiment supporting an overweight bias, an exceptional risk-reward setup, and provides details on various institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.", "age_days": 29.3, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "189bcbf04a6d7d25ee0b26ff4baa5bdcf280ba3830523fbca8215d4db2541bc4", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.stocktradersdaily.com/news_release/1/How_Belite_Bio_Inc_BLTE_Affects_Rotational_Strategy_Timing_080926065202_1786272722.html", "source_name": "Stock Traders Daily", "published_at": "2026-08-09T06:52:00", "source_names": ["Stock Traders Daily"], "target_scope": "How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing This article analyzes Belite Bio Inc (BLTE) and its impact on rotational trading strategies.", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 54, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 3e-06, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.47, "provider_symbols": ["BLTE", "BLTE.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Aug 2026 06:52", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BLTE", "provider_directional_mass": 0.4634}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Early balanced news score", "summary": "39 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 56, "display": "56", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 32, "display": "32", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 96, "display": "96%", "tone": "positive", "note": "39 company stories"}, {"label": "Story agreement", "value": 89, "display": "89", "tone": "positive", "note": "11/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 12, "note": "0.606 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "14 independent publishers"}, {"label": "Company relevance", "value": 96, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 44, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 89, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 69, "note": "less reliance on one publisher"}], "freshness": 44, "source_independence": 69, "timeline": [{"date": "2026-08-09", "label": "09 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-10", "label": "10 Aug", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 1, "score": 57, "tone": "neutral", "x": 105.2, "y": 122.3, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-08-12", "label": "12 Aug", "count": 3, "score": 73, "tone": "positive", "x": 136.8, "y": 93.1, "volume_height": 15.6, "volume_y": 250.4}, {"date": "2026-08-13", "label": "13 Aug", "count": 10, "score": 58, "tone": "positive", "x": 168.3, "y": 120.4, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-14", "label": "14 Aug", "count": 8, "score": 48, "tone": "neutral", "x": 199.9, "y": 138.6, "volume_height": 41.6, "volume_y": 224.4}, {"date": "2026-08-15", "label": "15 Aug", "count": 0, "score": null, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-16", "label": "16 Aug", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-17", "label": "17 Aug", "count": 0, "score": null, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-18", "label": "18 Aug", "count": 1, "score": 25, "tone": "negative", "x": 326.3, "y": 180.5, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-08-19", "label": "19 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-08-20", "label": "20 Aug", "count": 1, "score": 43, "tone": "neutral", "x": 389.4, "y": 147.7, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-08-21", "label": "21 Aug", "count": 3, "score": 50, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 15.6, "volume_y": 250.4}, {"date": "2026-08-22", "label": "22 Aug", "count": 0, "score": null, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-23", "label": "23 Aug", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-24", "label": "24 Aug", "count": 2, "score": 52, "tone": "neutral", "x": 515.8, "y": 131.4, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-25", "label": "25 Aug", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-26", "label": "26 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-27", "label": "27 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-28", "label": "28 Aug", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-29", "label": "29 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-30", "label": "30 Aug", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-31", "label": "31 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-01", "label": "01 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-09-02", "label": "02 Sep", "count": 0, "score": null, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-03", "label": "03 Sep", "count": 2, "score": 63, "tone": "positive", "x": 831.7, "y": 111.3, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-04", "label": "04 Sep", "count": 4, "score": 70, "tone": "positive", "x": 863.2, "y": 98.6, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-09-05", "label": "05 Sep", "count": 0, "score": null, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-06", "label": "06 Sep", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-07", "label": "07 Sep", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "42.0,135.0 105.2,122.3 136.8,93.1 168.3,120.4 199.9,138.6 326.3,180.5 357.9,135.0 389.4,147.7 421.0,135.0 515.8,131.4 768.5,135.0 831.7,111.3 863.2,98.6", "timeline_has_signal": true, "timeline_start": "09 Aug", "timeline_mid": "24 Aug", "timeline_end": "07 Sep", "momentum": {"label": "Stable but thin", "tone": "neutral", "recent_score": 67, "prior_score": 69, "delta": -2, "recent_count": 2, "prior_count": 4, "volume_delta": -2, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 68, "delta": null, "latest_count": 0, "baseline_count": 7, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 2, "share": 5}, {"label": "4 to 7 days", "count": 5, "share": 13}, {"label": "8 to 14 days", "count": 2, "share": 5}, {"label": "15 to 21 days", "count": 6, "share": 15}, {"label": "22 to 30 days", "count": 24, "share": 62}], "source_profile": [{"label": "Investing.com", "count": 6, "share": 15, "score": 69, "tone": "positive"}, {"label": "MarketBeat", "count": 6, "share": 15, "score": 53, "tone": "neutral"}, {"label": "Stock Titan", "count": 4, "share": 10, "score": 50, "tone": "neutral"}, {"label": "MT Newswires", "count": 3, "share": 8, "score": 63, "tone": "positive"}, {"label": "Sahm", "count": 2, "share": 5, "score": 57, "tone": "neutral"}, {"label": "www.marketscreener.com", "count": 2, "share": 5, "score": 51, "tone": "neutral"}, {"label": "GlobeNewswire", "count": 2, "share": 5, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Earnings", "count": 17, "share": 44, "score": 54, "tone": "neutral"}, {"label": "Analyst action", "count": 10, "share": 26, "score": 71, "tone": "positive"}, {"label": "Market update", "count": 9, "share": 23, "score": 50, "tone": "neutral"}, {"label": "Regulatory and legal", "count": 2, "share": 5, "score": 52, "tone": "neutral"}, {"label": "Balance sheet", "count": 1, "share": 3, "score": 43, "tone": "neutral"}], "topics": [{"label": "Life Sciences", "count": 27, "share": 69}, {"label": "Earnings", "count": 23, "share": 59}, {"label": "Financial Markets", "count": 16, "share": 41}, {"label": "Clinical Trials", "count": 11, "share": 28}, {"label": "Fda Approval", "count": 8, "share": 21}, {"label": "Biotech", "count": 6, "share": 15}, {"label": "Finance", "count": 4, "share": 10}, {"label": "Pharma", "count": 3, "share": 8}, {"label": "Rare Diseases", "count": 2, "share": 5}, {"label": "Ophthalmology", "count": 2, "share": 5}], "supporting": [{"label": "Direct evidence", "text": "39 current stories are mapped specifically to BLTE."}, {"label": "Source breadth", "text": "The score uses 14 publishers rather than depending on one outlet."}], "tempering": [{"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.606."}, {"label": "Confidence", "text": "Confidence is 32/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://www.marketscreener.com/news/belite-bio-shares-rise-after-canaccord-initiates-coverage-with-buy-rating-ce785bdbd980f126", "tier": "direct", "title": "Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Belite Bio's shares rose after Canaccord Genuity initiated coverage with a Buy rating and a $303 price target. This positive analyst coverage comes amidst other recent news for Belite Bio, including FDA Priority Review for its Stargardt Disease treatment, Tinlarebant. The company is focused on developing therapeutics for retinal degenerative eye diseases and metabolic conditions.", "age_days": 2.7, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/belite-bio-shares-rise-after-canaccord-initiates-coverage-with-buy-rating-ce785bdbd980f126", "source_name": "marketscreener.com", "published_at": "2026-09-04T19:40:09", "tone_signals": ["Analyst upgrade"], "company_focus": 0.78, "freshness_pct": 53.0, "sentiment_pct": 75, "evidence_basis": "archived_article", "evidence_share": 15.8, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.095502, "influence_label": "High", "event_confidence": 69, "company_focus_pct": 78, "evidence_strength": 58, "published_display": "04 Sep 2026 19:40", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "15.8"}, "article_count": 39, "updated_at": "2026-09-07T13:33:58.879792+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 133.5, "label": "13 Mar 2026", "close": 164.11, "index": 100.0}, {"x": 78.4, "y": 158.6, "label": "20 Mar 2026", "close": 154.59, "index": 94.2}, {"x": 114.9, "y": 165.3, "label": "27 Mar 2026", "close": 152.07, "index": 92.7}, {"x": 151.3, "y": 118.4, "label": "03 Apr 2026", "close": 169.85, "index": 103.5}, {"x": 187.7, "y": 110.7, "label": "10 Apr 2026", "close": 172.76, "index": 105.3}, {"x": 224.2, "y": 130.0, "label": "17 Apr 2026", "close": 165.45, "index": 100.8}, {"x": 260.6, "y": 141.1, "label": "24 Apr 2026", "close": 161.26, "index": 98.3}, {"x": 297.0, "y": 157.9, "label": "01 May 2026", "close": 154.85, "index": 94.4}, {"x": 333.5, "y": 157.9, "label": "08 May 2026", "close": 154.88, "index": 94.4}, {"x": 369.9, "y": 189.2, "label": "15 May 2026", "close": 143.0, "index": 87.1}, {"x": 406.3, "y": 204.2, "label": "22 May 2026", "close": 137.3, "index": 83.7}, {"x": 442.8, "y": 186.1, "label": "29 May 2026", "close": 144.18, "index": 87.9}, {"x": 479.2, "y": 188.3, "label": "05 Jun 2026", "close": 143.35, "index": 87.3}, {"x": 515.6, "y": 201.9, "label": "12 Jun 2026", "close": 138.16, "index": 84.2}, {"x": 552.0, "y": 181.0, "label": "19 Jun 2026", "close": 146.12, "index": 89.0}, {"x": 588.5, "y": 174.1, "label": "26 Jun 2026", "close": 148.73, "index": 90.6}, {"x": 624.9, "y": 179.6, "label": "03 Jul 2026", "close": 146.63, "index": 89.3}, {"x": 661.3, "y": 172.5, "label": "10 Jul 2026", "close": 149.33, "index": 91.0}, {"x": 697.8, "y": 170.5, "label": "17 Jul 2026", "close": 150.08, "index": 91.5}, {"x": 734.2, "y": 161.9, "label": "24 Jul 2026", "close": 153.36, "index": 93.4}, {"x": 770.6, "y": 148.0, "label": "31 Jul 2026", "close": 158.61, "index": 96.6}, {"x": 807.1, "y": 136.3, "label": "07 Aug 2026", "close": 163.05, "index": 99.4}, {"x": 843.5, "y": 137.0, "label": "14 Aug 2026", "close": 162.8, "index": 99.2}, {"x": 879.9, "y": 141.6, "label": "21 Aug 2026", "close": 161.06, "index": 98.1}, {"x": 916.4, "y": 166.2, "label": "28 Aug 2026", "close": 151.72, "index": 92.5}, {"x": 952.8, "y": 55.8, "label": "04 Sep 2026", "close": 193.61, "index": 118.0}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "tone": "neutral", "close": 148.73, "label": "26 Jun 2026", "score": 50, "stories": 4, "raw_score": 50, "confidence": 0, "price_change": 1.8, "x": 593.7, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "tone": "neutral", "close": 146.63, "label": "03 Jul 2026", "score": 50, "stories": 6, "raw_score": 50, "confidence": 0, "price_change": -1.4, "x": 630.1, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "tone": "neutral", "close": 149.33, "label": "10 Jul 2026", "score": 50, "stories": 8, "raw_score": 50, "confidence": 0, "price_change": 1.8, "x": 666.5, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "tone": "neutral", "close": 150.08, "label": "17 Jul 2026", "score": 50, "stories": 11, "raw_score": 50, "confidence": 0, "price_change": 0.5, "x": 703.0, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 153.36, "label": "24 Jul 2026", "score": 52, "stories": 16, "raw_score": 61, "confidence": 26, "price_change": 2.2, "x": 739.4, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "neutral", "close": 158.61, "label": "31 Jul 2026", "score": 52, "stories": 22, "raw_score": 61, "confidence": 27, "price_change": 3.4, "x": 775.8, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "neutral", "close": 163.05, "label": "07 Aug 2026", "score": 51, "stories": 27, "raw_score": 61, "confidence": 19, "price_change": 2.8, "x": 812.3, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 162.8, "label": "14 Aug 2026", "score": 57, "stories": 49, "raw_score": 60, "confidence": 56, "price_change": -0.2, "x": 848.7, "y": 117.1, "show_label": false, "label_y": 107.1}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "tone": "neutral", "close": 161.06, "label": "21 Aug 2026", "score": 52, "stories": 49, "raw_score": 54, "confidence": 34, "price_change": -1.1, "x": 885.1, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "tone": "neutral", "close": 151.72, "label": "28 Aug 2026", "score": 51, "stories": 41, "raw_score": 54, "confidence": 22, "price_change": -5.8, "x": 921.6, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "tone": "positive", "close": 193.61, "label": "04 Sep 2026", "score": 58, "stories": 43, "raw_score": 67, "confidence": 39, "price_change": 27.6, "x": 958.0, "y": 115.3, "show_label": true, "label_y": 105.3}], "price_path": "42.0,133.5 78.4,158.6 114.9,165.3 151.3,118.4 187.7,110.7 224.2,130.0 260.6,141.1 297.0,157.9 333.5,157.9 369.9,189.2 406.3,204.2 442.8,186.1 479.2,188.3 515.6,201.9 552.0,181.0 588.5,174.1 624.9,179.6 661.3,172.5 697.8,170.5 734.2,161.9 770.6,148.0 807.1,136.3 843.5,137.0 879.9,141.6 916.4,166.2 952.8,55.8", "sentiment_path": "593.7,130.0 630.1,130.0 666.5,130.0 703.0,130.0 739.4,126.3 775.8,126.3 812.3,128.2 848.7,117.1 885.1,126.3 921.6,128.2 958.0,115.3", "score_version": "evidence-v10", "price_change": 18.0, "sentiment_change": 8, "recent_pairs": [{"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "tone": "positive", "close": 193.61, "label": "04 Sep 2026", "score": 58, "stories": 43, "raw_score": 67, "confidence": 39, "price_change": 27.6, "x": 958.0, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "tone": "neutral", "close": 151.72, "label": "28 Aug 2026", "score": 51, "stories": 41, "raw_score": 54, "confidence": 22, "price_change": -5.8, "x": 921.6, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "tone": "neutral", "close": 161.06, "label": "21 Aug 2026", "score": 52, "stories": 49, "raw_score": 54, "confidence": 34, "price_change": -1.1, "x": 885.1, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 162.8, "label": "14 Aug 2026", "score": 57, "stories": 49, "raw_score": 60, "confidence": 56, "price_change": -0.2, "x": 848.7, "y": 117.1, "show_label": false, "label_y": 107.1}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "neutral", "close": 163.05, "label": "07 Aug 2026", "score": 51, "stories": 27, "raw_score": 61, "confidence": 19, "price_change": 2.8, "x": 812.3, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "neutral", "close": 158.61, "label": "31 Jul 2026", "score": 52, "stories": 22, "raw_score": 61, "confidence": 27, "price_change": 3.4, "x": 775.8, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 153.36, "label": "24 Jul 2026", "score": 52, "stories": 16, "raw_score": 61, "confidence": 26, "price_change": 2.2, "x": 739.4, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "tone": "neutral", "close": 150.08, "label": "17 Jul 2026", "score": 50, "stories": 11, "raw_score": 50, "confidence": 0, "price_change": 0.5, "x": 703.0, "y": 130.0, "show_label": false, "label_y": 120.0}], "reconstructed": true, "latest_close": 193.61, "price_observations": 26, "sentiment_observations": 11, "sentiment_start_label": "26 Jun 2026", "sentiment_end_label": "04 Sep 2026", "sentiment_history_limited": false, "price_axis_high": 122.1, "price_axis_mid": 100.8, "price_axis_low": 79.5, "start_label": "13 Mar", "mid_label": "09 Jun", "end_label": "04 Sep", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"tone": "neutral", "delta": 0, "label": "21 Jun 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "21 Jun", "collected_at": "2026-06-21T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start"}, {"tone": "neutral", "delta": 0, "label": "22 Jun 23:59", "score": 50, "height": 4, "articles": 2, "confidence": 0, "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "24 Jun 23:59", "score": 50, "height": 4, "articles": 3, "confidence": 0, "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "25 Jun 23:59", "score": 50, "height": 4, "articles": 4, "confidence": 0, "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "27 Jun 23:59", "score": 50, "height": 4, "articles": 5, "confidence": 0, "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "30 Jun 23:59", "score": 50, "height": 4, "articles": 6, "confidence": 0, "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "05 Jul 23:59", "score": 50, "height": 4, "articles": 7, "confidence": 0, "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "09 Jul 23:59", "score": 50, "height": 4, "articles": 8, "confidence": 0, "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "15 Jul 23:59", "score": 50, "height": 4, "articles": 10, "confidence": 0, "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "17 Jul 23:59", "score": 50, "height": 4, "articles": 11, "confidence": 0, "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "20 Jul 23:59", "score": 51, "height": 4, "articles": 13, "confidence": 27, "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 27, "score_change_display": "+1"}, {"tone": "neutral", "delta": 0, "label": "21 Jul 23:59", "score": 50, "height": 4, "articles": 13, "confidence": 23, "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "-1"}, {"tone": "neutral", "delta": 3, "label": "22 Jul 23:59", "score": 53, "height": 6, "articles": 14, "confidence": 32, "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score_change": 3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 9, "score_change_display": "+3"}, {"tone": "neutral", "delta": 2, "label": "23 Jul 23:59", "score": 52, "height": 4, "articles": 16, "confidence": 29, "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "24 Jul 23:59", "score": 52, "height": 4, "articles": 16, "confidence": 26, "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "25 Jul 23:59", "score": 52, "height": 4, "articles": 19, "confidence": 29, "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "26 Jul 23:59", "score": 52, "height": 4, "articles": 20, "confidence": 27, "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "27 Jul 23:59", "score": 52, "height": 4, "articles": 21, "confidence": 25, "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "31 Jul 23:59", "score": 52, "height": 4, "articles": 22, "confidence": 27, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "03 Aug 23:59", "score": 51, "height": 4, "articles": 24, "confidence": 23, "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "-1"}, {"tone": "neutral", "delta": 1, "label": "05 Aug 23:59", "score": 51, "height": 4, "articles": 24, "confidence": 21, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "06 Aug 23:59", "score": 51, "height": 4, "articles": 26, "confidence": 20, "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "07 Aug 23:59", "score": 51, "height": 4, "articles": 27, "confidence": 19, "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "08 Aug 23:59", "score": 52, "height": 4, "articles": 27, "confidence": 29, "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 10, "score_change_display": "+1"}, {"tone": "neutral", "delta": 2, "label": "09 Aug 23:59", "score": 52, "height": 4, "articles": 29, "confidence": 27, "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "11 Aug 23:59", "score": 52, "height": 4, "articles": 30, "confidence": 28, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "+0"}, {"tone": "positive", "delta": 9, "label": "12 Aug 23:59", "score": 59, "height": 18, "articles": 33, "confidence": 37, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 7, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 9, "score_change_display": "+7"}, {"tone": "positive", "delta": 9, "label": "13 Aug 23:59", "score": 59, "height": 18, "articles": 43, "confidence": 48, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 10, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 11, "score_change_display": "+0"}, {"tone": "neutral", "delta": 7, "label": "14 Aug 23:59", "score": 57, "height": 14, "articles": 49, "confidence": 56, "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 6, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 8, "score_change_display": "-2"}, {"tone": "neutral", "delta": 3, "label": "18 Aug 23:59", "score": 53, "height": 6, "articles": 49, "confidence": 41, "short_label": "18 Aug", "collected_at": "2026-08-18T23:59:59.999999+00:00", "score_change": -4, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -15, "score_change_display": "-4"}, {"tone": "neutral", "delta": 3, "label": "19 Aug 23:59", "score": 53, "height": 6, "articles": 48, "confidence": 38, "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "20 Aug 23:59", "score": 52, "height": 4, "articles": 48, "confidence": 37, "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -1, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "21 Aug 23:59", "score": 52, "height": 4, "articles": 49, "confidence": 34, "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "24 Aug 23:59", "score": 52, "height": 4, "articles": 44, "confidence": 28, "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -5, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "01 Sep 23:59", "score": 51, "height": 4, "articles": 40, "confidence": 19, "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -9, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "03 Sep 23:59", "score": 52, "height": 4, "articles": 40, "confidence": 29, "short_label": "03 Sep", "collected_at": "2026-09-03T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 10, "score_change_display": "+1"}, {"tone": "positive", "delta": 8, "label": "04 Sep 23:59", "score": 58, "height": 16, "articles": 43, "confidence": 39, "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score_change": 6, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 10, "score_change_display": "+6"}, {"tone": "neutral", "delta": 5, "label": "07 Sep 13:33", "score": 55, "height": 10, "articles": 39, "confidence": 30, "short_label": "07 Sep", "collected_at": "2026-09-07T13:33:58.431377+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -9, "score_change_display": "-3"}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 38, "span_label": "78 days", "first_score": 50, "latest_score": 55, "net_change": 5, "net_change_display": "+5", "direction": "Strengthening", "high_score": 59, "low_score": 50, "latest_confidence": 30, "confidence_change": 30, "latest_articles": 39, "article_change": 38, "latest_label": "07 Sep 13:33", "latest_evidence_label": "Provisional", "chart_rows": [{"tone": "neutral", "delta": 0, "label": "21 Jun 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "21 Jun", "collected_at": "2026-06-21T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start", "x": 42.0, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "22 Jun 23:59", "score": 50, "height": 4, "articles": 2, "confidence": 0, "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 66.8, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "24 Jun 23:59", "score": 50, "height": 4, "articles": 3, "confidence": 0, "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 91.5, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "25 Jun 23:59", "score": 50, "height": 4, "articles": 4, "confidence": 0, "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 116.3, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "27 Jun 23:59", "score": 50, "height": 4, "articles": 5, "confidence": 0, "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 141.0, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "30 Jun 23:59", "score": 50, "height": 4, "articles": 6, "confidence": 0, "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 165.8, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "05 Jul 23:59", "score": 50, "height": 4, "articles": 7, "confidence": 0, "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 190.5, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "09 Jul 23:59", "score": 50, "height": 4, "articles": 8, "confidence": 0, "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 215.3, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "15 Jul 23:59", "score": 50, "height": 4, "articles": 10, "confidence": 0, "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 240.1, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "17 Jul 23:59", "score": 50, "height": 4, "articles": 11, "confidence": 0, "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 264.8, "y": 135.0}, {"tone": "neutral", "delta": 1, "label": "20 Jul 23:59", "score": 51, "height": 4, "articles": 13, "confidence": 27, "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 27, "score_change_display": "+1", "x": 289.6, "y": 133.2}, {"tone": "neutral", "delta": 0, "label": "21 Jul 23:59", "score": 50, "height": 4, "articles": 13, "confidence": 23, "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "-1", "x": 314.3, "y": 135.0}, {"tone": "neutral", "delta": 3, "label": "22 Jul 23:59", "score": 53, "height": 6, "articles": 14, "confidence": 32, "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score_change": 3, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 9, "score_change_display": "+3", "x": 339.1, "y": 129.5}, {"tone": "neutral", "delta": 2, "label": "23 Jul 23:59", "score": 52, "height": 4, "articles": 16, "confidence": 29, "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "-1", "x": 363.8, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "24 Jul 23:59", "score": 52, "height": 4, "articles": 16, "confidence": 26, "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+0", "x": 388.6, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "25 Jul 23:59", "score": 52, "height": 4, "articles": 19, "confidence": 29, "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 3, "score_change_display": "+0", "x": 413.4, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "26 Jul 23:59", "score": 52, "height": 4, "articles": 20, "confidence": 27, "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 438.1, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "27 Jul 23:59", "score": 52, "height": 4, "articles": 21, "confidence": 25, "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 462.9, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "31 Jul 23:59", "score": 52, "height": 4, "articles": 22, "confidence": 27, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 2, "score_change_display": "+0", "x": 487.6, "y": 131.4}, {"tone": "neutral", "delta": 1, "label": "03 Aug 23:59", "score": 51, "height": 4, "articles": 24, "confidence": 23, "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "-1", "x": 512.4, "y": 133.2}, {"tone": "neutral", "delta": 1, "label": "05 Aug 23:59", "score": 51, "height": 4, "articles": 24, "confidence": 21, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 537.1, "y": 133.2}, {"tone": "neutral", "delta": 1, "label": "06 Aug 23:59", "score": 51, "height": 4, "articles": 26, "confidence": 20, "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 561.9, "y": 133.2}, {"tone": "neutral", "delta": 1, "label": "07 Aug 23:59", "score": 51, "height": 4, "articles": 27, "confidence": 19, "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 586.6, "y": 133.2}, {"tone": "neutral", "delta": 2, "label": "08 Aug 23:59", "score": 52, "height": 4, "articles": 27, "confidence": 29, "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 10, "score_change_display": "+1", "x": 611.4, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "09 Aug 23:59", "score": 52, "height": 4, "articles": 29, "confidence": 27, "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 636.2, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "11 Aug 23:59", "score": 52, "height": 4, "articles": 30, "confidence": 28, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "+0", "x": 660.9, "y": 131.4}, {"tone": "positive", "delta": 9, "label": "12 Aug 23:59", "score": 59, "height": 18, "articles": 33, "confidence": 37, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 7, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 9, "score_change_display": "+7", "x": 685.7, "y": 118.6}, {"tone": "positive", "delta": 9, "label": "13 Aug 23:59", "score": 59, "height": 18, "articles": 43, "confidence": 48, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 10, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 11, "score_change_display": "+0", "x": 710.4, "y": 118.6}, {"tone": "neutral", "delta": 7, "label": "14 Aug 23:59", "score": 57, "height": 14, "articles": 49, "confidence": 56, "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 6, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 8, "score_change_display": "-2", "x": 735.2, "y": 122.3}, {"tone": "neutral", "delta": 3, "label": "18 Aug 23:59", "score": 53, "height": 6, "articles": 49, "confidence": 41, "short_label": "18 Aug", "collected_at": "2026-08-18T23:59:59.999999+00:00", "score_change": -4, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -15, "score_change_display": "-4", "x": 759.9, "y": 129.5}, {"tone": "neutral", "delta": 3, "label": "19 Aug 23:59", "score": 53, "height": 6, "articles": 48, "confidence": 38, "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+0", "x": 784.7, "y": 129.5}, {"tone": "neutral", "delta": 2, "label": "20 Aug 23:59", "score": 52, "height": 4, "articles": 48, "confidence": 37, "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -1, "score_change_display": "-1", "x": 809.5, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "21 Aug 23:59", "score": 52, "height": 4, "articles": 49, "confidence": 34, "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+0", "x": 834.2, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "24 Aug 23:59", "score": 52, "height": 4, "articles": 44, "confidence": 28, "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -5, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "+0", "x": 859.0, "y": 131.4}, {"tone": "neutral", "delta": 1, "label": "01 Sep 23:59", "score": 51, "height": 4, "articles": 40, "confidence": 19, "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -9, "score_change_display": "-1", "x": 883.7, "y": 133.2}, {"tone": "neutral", "delta": 2, "label": "03 Sep 23:59", "score": 52, "height": 4, "articles": 40, "confidence": 29, "short_label": "03 Sep", "collected_at": "2026-09-03T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 10, "score_change_display": "+1", "x": 908.5, "y": 131.4}, {"tone": "positive", "delta": 8, "label": "04 Sep 23:59", "score": 58, "height": 16, "articles": 43, "confidence": 39, "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score_change": 6, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 10, "score_change_display": "+6", "x": 933.2, "y": 120.4}, {"tone": "neutral", "delta": 5, "label": "07 Sep 13:33", "score": 55, "height": 10, "articles": 39, "confidence": 30, "short_label": "07 Sep", "collected_at": "2026-09-07T13:33:58.431377+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -9, "score_change_display": "-3", "x": 958.0, "y": 125.9}], "chart_points": "42.0,135.0 66.8,135.0 91.5,135.0 116.3,135.0 141.0,135.0 165.8,135.0 190.5,135.0 215.3,135.0 240.1,135.0 264.8,135.0 289.6,133.2 314.3,135.0 339.1,129.5 363.8,131.4 388.6,131.4 413.4,131.4 438.1,131.4 462.9,131.4 487.6,131.4 512.4,133.2 537.1,133.2 561.9,133.2 586.6,133.2 611.4,131.4 636.2,131.4 660.9,131.4 685.7,118.6 710.4,118.6 735.2,122.3 759.9,129.5 784.7,129.5 809.5,131.4 834.2,131.4 859.0,131.4 883.7,133.2 908.5,131.4 933.2,120.4 958.0,125.9", "changes": [{"tone": "neutral", "delta": 5, "label": "07 Sep 13:33", "score": 55, "height": 10, "articles": 39, "confidence": 30, "short_label": "07 Sep", "collected_at": "2026-09-07T13:33:58.431377+00:00", "score_change": -3, "reconstructed": true, "score_version": "evidence-v10", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -9, "score_change_display": "-3"}, {"tone": "positive", "delta": 8, "label": "04 Sep 23:59", "score": 58, "height": 16, "articles": 43, "confidence": 39, "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score_change": 6, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": 10, "score_change_display": "+6"}, {"tone": "neutral", "delta": 2, "label": "03 Sep 23:59", "score": 52, "height": 4, "articles": 40, "confidence": 29, "short_label": "03 Sep", "collected_at": "2026-09-03T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 10, "score_change_display": "+1"}, {"tone": "neutral", "delta": 1, "label": "01 Sep 23:59", "score": 51, "height": 4, "articles": 40, "confidence": 19, "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -9, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "24 Aug 23:59", "score": 52, "height": 4, "articles": 44, "confidence": 28, "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -5, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "21 Aug 23:59", "score": 52, "height": 4, "articles": 49, "confidence": 34, "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "20 Aug 23:59", "score": 52, "height": 4, "articles": 48, "confidence": 37, "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 0, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -1, "score_change_display": "-1"}, {"tone": "neutral", "delta": 3, "label": "19 Aug 23:59", "score": 53, "height": 6, "articles": 48, "confidence": 38, "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": -1, "evidence_label": "Measured", "evidence_status": "measured", "confidence_change": -3, "score_change_display": "+0"}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}